FI100798B - Process for the preparation of compounds useful in the preparation of antibacterial agents - Google Patents

Description

100798

Process for the Preparation of Compounds Useful in the Preparation of Antibacterial Agents (Separated from Application No. 903696) U.S. Patent 4,341,784 discloses certain substituted 7- (3-amino-1-pyrrolidinyl) -1-ethyl-6-fluoro-1,4-dihydro- 4-Oxo-1,8-naphthyridine-3-carboxylic acids of general formula

O

ΧΧΧνΧΧΧ V ™

NHR

The compounds have been shown to have antibacterial activity.

The Journal of Medicinal Chemistry, 23, 1358 (1980) deals with certain substituted quinoline-3-carboxylic acids having the structural formula 0

qXXX

c2h5 wherein -N J may be pyrrolidinyl. See also U.S. Patent 4 / 146,719. The compounds have been shown to have antibacterial activity.

Certain 7-heterocyclic substituted 1,8-naphthyridines are disclosed in Eur.J.Med.Chem. - Chemica Thera-peutica, 29, 27 (1977). U.S. Patents 3,753,993 and 3,907,808 disclose certain 7-pyridylquinolones.

European Patent Applications 229,635 and 206,101 cover certain 1,8-bridged 1,4-dihydro-4-quinolinones of formula 2 100798 X50

Xl C ° 2H

X "X ^ N '^ ^ (CRiR2) tn (CR3R4) n-f ^ A

EvB

wherein is hydrogen, NO 2, 1-3C-alkyl or halogen, X 2 is halogen, 1-3C-alkyl, 1-3C-alkylsulphenyl or optionally substituted phenylsulphenyl, X 5 is hydrogen, halogen or methyl.

U.S. Patent 4,774,246 discloses certain substituted 1-phenyl-6,8-difluoro-1,4-dihydro-4-oxo-7- (1-piperazinyl) -quinoline-3-carboxylic acids of general formula 9o U.S. Patent 4,704,459 describes a process for the preparation of certain 1-substituted aryl-1,4-dihydro-4-oxonaphthyridine derivatives of the general formula

O

FNY ^ vJkvXC00R '

-.-V

Jn. X

oT

F

U.S. Pat. No. 3,100798 4,649,144 discloses certain 1,8-naphthyridine derivatives of the general formula CXJÖ ~

RlNH

U.S. Patent 4,571,396 relates to certain naphthyridine, quinoline and benzoxazinecarboxylic acids having a crosslinked side chain at the 7-position.

Co-pending U.S. Patent Application 080,113 discloses certain naphthyridine, quinoline and benzoxazine carboxylic acids having a crosslinked side chain at the 7-position and hydrogen, fluorine or amino at the 5-position.

The references indicate that these compounds have antibacterial activity.

The parent application of this invention and the application 942505 separated therefrom disclose the compounds of formula I r3 o

XXX

r2 100798 4 or pharmaceutically acceptable acid addition or base salts thereof, wherein Z is NR5R5 / v (CR5R6) n ^ R4-NN- or] \, N - r7

Rn 'Rn * * - / J \ - r-nSn- ^ XD * -

RSX

NN - a wherein R 4 is hydrogen, alkyl of 1 to 4 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, R 'is hydrogen, hydroxyl, alkyl of 1 to 4 carbon atoms, phenyl or phenyl substituted by halogen, alkyl or alkoxy , n is an integer from 0 to 4, R 5 and R f are each independently hydrogen, lower alkyl or cycloalkyl, X is CH, CF, CC 1, CBr, N, CCF 3, CNH 2, CNO 2, CR or COR ", wherein R is lower alkyl and R "is hydrogen or lower alkyl, R 3 is lower, straight chain, branched or cyclic, alkyl of 1 to 3 carbon atoms, R 2 is alkyl of 1 to 4 100798 carbon atoms, vinyl, haloalkyl, hydroxyalkyl of 2 to 4 carbon atoms, alkyl of 3 to 6 carbon atoms cycloalkyl, phenyl or phenyl substituted by halogen, alkyl, NH 2 or OH is hydrogen, alkyl having 1 to 6 carbon atoms or a cation.

Preferred compounds are those wherein X is CH, CF, CC1 or N.

Preferred compounds are also those wherein R 2 is cyclopropyl, ethyl or 2,4-difluorophenyl.

Other preferred compounds are those wherein R 3 is methyl, ethyl, isopropyl or cyclopropyl.

Other preferred compounds are those wherein R 1 is hydrogen or a pharmaceutically acceptable base salt such as a metal or amine salt.

Other preferred compounds are those in which Z is NRsRfi (CR5R6) n n '') H / ~ 7 \ ψ μ

R 11 'K' wherein R 4 is hydrogen or methyl, R 'is hydrogen or methyl, n is 0, 1 or 2, R 5 and R 6 are each independently hydrogen or methyl.

Particularly preferred are compounds wherein Z is a group 6 100798 HN ^ - CH3N ^ - CH3 Υλ / -λ HN N— HN N - /> - 7 - y— 'CH3 C »3 ch3" "2C-." O-.

. ΗζΝΎ / ~, r <c "" CH2Y- I N— HNCH3 l / N ~ h2n “2γΑ H2NVTn-

HNC2H5, tal H ^ V-V

The most preferred compounds are those wherein X is CH, CF, CCl, R 2 is cyclopropyl, R 3 is CH 3, Et, R 1 is H and Z is 7 100798 V '-. Ο η '”Ό“ - - "20- ch3

Particularly preferred compounds are: 1-cyclopropyl-6,8-difluoro-1,4-dihydro-5-methyl-4-oxo-7- (1-piperazinyl) -3-quinolinecarboxylic acid; 7- (3-amino-1-pyrrolidinyl) -1-cyclopropyl-6,8-difluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid; l-cyclopropyl-7- [3 - [(ethylamino) methyl] -L-pyrrolidine-carbonyl] -6,8-difluoro-l, 4-dihydro-5-methyl-4-oxo-3-quinolin-liinikarboksyylihappo; 7- [3- (aminomethyl) -3-methyl-l-pyrrolidinyl] -1-cyclopropyl-6,8-difluoro-l, 4-dihydro-5-methyl-4-oxo-3-quinolin-liinikarboksyylihappo; l-cyclopropyl-6,8-difluoro-l, 4-dihydro-5-methyl-7- [3-methyl-l-piperazinyl] -4-oxo-3-kinoliinikarboksyyli acid; l-cyclopropyl-6-fluoro-l, 4-dihydro-5-methyl-4-oxo-7- (l-piperazinyl) -3-quinolinecarboxylic acid; l-cyclopropyl-6-fluoro-l, 4-dihydro-5-methyl-7- (3-methyl-l-piperazinyl) -4-oxo-3-quinolinecarboxylic acid; 7- (3-amino-1-pyrrolidinyl) -1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid; 6-Fluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-7- (3-methyl-1-piperazinyl-4-oxo-3-quinolinecarboxylic acid; 7- (3- amino-1-pyrrolidinyl) -6-fluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid; 7- [3- (aminomethyl) - 3-methyl-1-pyrrolidinyl] -6-fluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid; 8 100798 7- [3- (endo-amino) -8-azabicyclo [3.2.1] oct-8-yl] -8-chloro-1-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3 - quinolinecarboxylic acid, and pharmaceutically acceptable acid addition or base salts thereof.

Other preferred compounds are: 1-cyclopropyl-6,8-difluoro-1,4-dihydro-5-ethyl-7- [3-methyl-1-piperazinyl] -4-oxo-3-quinolinecarboxylic acid; 7- (3-amino-1-pyrrolidinyl) -1-cyclopropyl-5-ethyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 7- (3-amino-1-pyrrolidinyl) -1,5-dicyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; l-cyclopropyl-7- [3 - [(ethylamino) methyl] -1-pyrrolidin-carbonyl] -6-fluoro-l, 4-dihydro-5-methyl-4-oxo-3-quinoline-carboxylic acid; 7- [3- (aminomethyl) -3-methyl-1-pyrrolidinyl] -1-cyclopropyl-6-fluoro-l, 4-dihydro-5-methyl-4-oxo-3-quinolin-acid A; 7- [3-amino-1-pyrrolidinyl) -8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid; 8-chloro-1-cyclopropyl-7- [3 - [(ethylamino) methyl] -1-pyrrolidinyl] -6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid; 8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-7- (1-piperazinyl) -3-quinolinecarboxylic acid; 8-chloro-l-cyclopropyl-6-fluoro-l, 4-dihydro-5-methyl-7- (3-methyl-l-piperazinyl) -4-oxo-3-kinoliinikarbok-carboxylic acid; 7- [3- (aminomethyl) -3-methyl-l-pyrrolidinyl] -8-chloro-l-cyclopropyl-6-fluoro-l, 4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid; 9 100798 7- (3-amino-1-pyrrolidinyl) -8-bromo-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid; 8-bromo-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7- (3-methyl-1-piperazinyl) -4-oxo-3-quinolinecarboxylic acid; 7- [3- (aminomethyl) -3-methyl-1-pyrrolidinyl] -8-bromo-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid; 7- (3-amino-1-pyrrolidinyl) -1-cyclopropyl-6-fluoro-1,4-dihydro-8-hydroxy-5-methyl-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-7- [3 - [(ethylamino) methyl] -1-pyrrolidinyl] -6-fluoro-1,4-dihydro-8-hydroxy-5-methyl-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-1,4-dihydro-8-hydroxy-5-methyl-4-oxo-7- (1-piperazinyl) -3-quinolinecarboxylic acid; 7- (3-amino-1-pyrrolidinyl) -1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-5-methyl-4-oxo-3-quinolinecarboxylic acid; l-cyclopropyl-7- [3 - [(ethylamino) methyl] -l-pyrrolidin-phenyl] -6-fluoro-l, 4-dihydro-8-methoxy-5-methyl-4-oxo-3-quinolinecarboxylic acid; l-cyclopropyl-6-fluoro-l, 4-dihydro-8-methoxy-7- (3-methyl-l-piperazinyl) -5-methyl-4-oxo-3-kinoliinikarbok-carboxylic acid; 7- (3-amino-1-pyrrolidinyl) -1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-8-nitro-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7- (3-methyl-1-piperazinyl) -8-nitro-4-oxo-3-quinolinecarboxylic acid; 7- [3- (aminomethyl) -3-methyl-l-pyrrolidinyl] -1-cyclopropyl-6-fluoro-l, 4-dihydro-5-methyl-8-nitro-4-oxo-3-quinolinecarboxylic acid; 100798 8-Amino-7- (3-amino-1-pyrrolidinyl) -1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid; 8-amino-l-cyclopropyl-6-fluoro-l, 4-dihydro-5-methyl-7- (3-methyl-l-piperazinyl) -4-oxo-3-kinoliinikarboksyy-acid; 8-amino-7- [3- (aminomethyl-3-methyl-1-pyrrolidinyl] -1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid; 3-Amino-1-pyrrolidinyl) -1-cyclopropyl-6-fluoro-5-methyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1-cyclopropyl-6-fluoro -1,4-dihydro-5-methyl-7- (3-methyl-1-piperazinyl) -4-oxo-1,8-naphthyridine-3-carboxylic acid; 1-cyclopropyl-5-ethyl-6-fluoro -1,4-dihydro-4-oxo-7- (1-piperazinyl) -1,8-naphthyridine-3-carboxylic acid; 7- (3-amino-1-pyrrolidinyl) -6,8-difluoro-1- ( 2,4-Difluoro-phenyl) -1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid 6.8-Difluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5 Methyl-7- (3-methyl-1-piperazinyl) -4-oxo-3-quinolinecarboxylic acid, 7- [3- (aminomethyl) -3-methyl-1-pyrrolidinyl] -6,8-di -Fluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid 7- (3-amino-1-pyrrolidinyl) -1-ethyl-6,8 difluoro-l, 4-dihydro-5-methyl-4-oxo-3-kinoliinikarboksyylihapp No; 1-ethyl-7- [3 - [(ethylamino) methyl] -1-pyrrolidinyl] -6,8-difluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid; '7- (3-amino-1-pyrrolidinyl) -6,8-difluoro-1- (2-fluoroethyl) -1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid; 6.8-difluoro-1- (2-fluoroethyl) -1,4-dihydro-5-methyl-4-oxo-7- (1-piperazinyl) -3-quinolinecarboxylic acid; 11 100798 7- (3-amino-1-pyrrolidinyl) -6,8-difluoro-1,4-dihydro-5-methyl-4-oxo-1-vinyl-3-quinolinecarboxylic acid; 6.8-difluoro-1,4-dihydro-5-methyl-4-oxo-7- (1-piperazinyl) -1-vinyl-3-quinolinecarboxylic acid; 6.8-difluoro-1,4-dihydro-5-methyl-7- (3-methyl-1-piperazinyl) -4-oxo-1-vinyl-3-quinolinecarboxylic acid; 7- (3-amino-l-pyrrolidinyl) -6-fluoro-L- (2,4-difluorophenyl-phenyl) -1,4-dihydro-5-methyl-4-oxo-3-kinoliinikarboksyy-acid; 6-fluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-7- (3,5-dimethyl-1-piperazinyl) -4-oxo-3-quinolinecarboxylic acid; 7- (3-amino-1-pyrrolidinyl) -1-ethyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid; l-ethyl-6-fluoro-l, 4-dihydro-5-methyl-4-oxo-7- (1-Pipe-piperazinyl) -3-quinolinecarboxylic acid; 7- [3 - [(ethylamino) methyl] -l-pyrrolidinyl) -6-fluoro-1- (2-fluoroethyl) -l, 4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid; 6-fluoro-1- (2-fluoroethyl) -1,4-dihydro-5-methyl-7- (3-methyl-1-piperazinyl) -4-oxo-3-quinolinecarboxylic acid; 7- (3-amino-1-pyrrolidinyl) -6-fluoro-1- (2-fluoroethyl) -1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid; . 7- (3-amino-1-pyrrolidinyl) -6-fluoro-1,4-dihydro-5-methyl-4-oxo-1-vinyl-3-quinolinecarboxylic acid; 6-fluoro-l, 4-dihydro-5-methyl-7- (3,5-dimethyl-piperazin-l-piperazinyl) -4-oxo-l-vinyl-3-quinolinecarboxylic acid; 8-chloro-7- (3-amino-1-pyrrolidinyl) -6-fluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid; 8-chloro-6-fluoro-L- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-7- (3-methyl-l-piperazinyl) -4-oxo-3-quinoline-carboxylic acid; 7- [3- (aminomethyl) -3-methyl-1-pyrrolidinyl] -8-chloro-6-fluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-4-oxo- 3-quinolinecarboxylic acid; 8-chloro-6-fluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-7- (3,5-dimethyl-1-piperazinyl) -4-oxo-3-quino- liinikarboksyylihappo; 8-chloro-l-ethyl-6-fluoro-l, 4-dihydro-5-methyl-4-oxo-7-piperazinyl-3-quinolinecarboxylic acid; 7- (3-amino-1-pyrrolidinyl) -8-chloro-1-ethyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid; 8-Chloro-1-ethyl-7- [3 - [(ethylamino) methyl] -1-pyrrolidinyl] -6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid ; 7- (3-amino-1-pyrrolidinyl) -8-chloro-6-fluoro-1- (2-fluoroethyl) -1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid; 8-chloro-6-fluoro-1- (2-fluoroethyl) -1,4-dihydro-5-methyl-7- (3-methyl-1-piperazinyl) -4-oxo-3-quinolinecarboxylic acid; 7- (3-amino-1-pyrrolidinyl) -8-chloro-6-fluoro-1,4-dihydro-5-methyl-4-oxo-1-vinyl-3-quinolinecarboxylic acid; 8-chloro-6-fluoro-1,4-dihydro-5-methyl-4-oxo-7- (1-piperazinyl) -1-vinyl-3-quinolinecarboxylic acid; 7- (3-amino-l-pyrrolidinyl) -l-cyclopropyl-6-fluoro-l, 4-dihydro-5,8-dimethyl-4-oxo-3-quinolinecarboxylic acid; l-cyclopropyl-6-fluoro-l, 4-dihydro-5,8-dimethyl-4-oxo-7- (l-piperazinyl) -3-quinolinecarboxylic acid; l-cyclopropyl-6-fluoro-l, 4-dihydro-5,8-dimethyl-7- (3-methyl-l-piperazinyl) -4-oxo-3-kinoliinikarboksyyli acid; 7- [3- (aminomethyl) -3-methyl-1-pyrrolidinyl] -1-cyclopropyl-6-fluoro-1,4-dihydro-5,8-dimethyl-4-oxo-3-quinolinecarboxylic acid ; l-cyclopropyl-7- [3 - [(ethylamino) methyl] -l-pyrrolidin-phenyl] -6-fluoro-l, 4-dihydro-5,8-dimethyl-4-oxo-3-quinolin-liinikarboksyylihappo; 13 100798 7- (3-Amino-1-pyrrolidinyl) -6-fluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5,8-dimethyl-4-oxo-3-quinolinecarboxylate acid; 6-fluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5,8-dimethyl-7- (3-methyl-1-piperazinyl) -4-oxo-3-quinolinecarboxylic acid; 7- [3- (aminomethyl) -3-methyl-1-pyrrolidinyl] -6-fluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5,8-dimethyl-4-oxo- 3-quinolinecarboxylic acid; 7- (3-amino-l-pyrrolidinyl) -l-ethyl-6-fluoro-l, 4-dihydro-ro-5,8-dimethyl-4-oxo-3-quinolinecarboxylic acid; 1-ethyl-6-fluoro-1,4-dihydro-5,8-dimethyl-7- (3-methyl-1-piperazinyl) -4-oxo-3-quinolinecarboxylic acid; 7- (3-amino-l-pyrrolidinyl) -l-cyclopropyl-6-fluoro-8-trifluoromethyl-l, 4-dihydro-5-methyl-4-oxo-3-quinoline-carboxylic acid; 1-cyclopropyl-6-fluoro-8-trifluoromethyl-1,4-dihydro-5-methyl-4-oxo-7- (1-piperazinyl) -3-quinolinecarboxylic acid; l-cyclopropyl-6-fluoro-8-trifluoromethyl-l, 4-dihydro-5-methyl-7- (3-methyl-l-piperazinyl) -4-oxo-3-quinoline-carboxylic acid; 7- [3- (aminomethyl) -3-methyl-1-pyrrolidinyl] -1-cyclopropyl-6-fluoro-8-trifluoromethyl-1,4-dihydro-5-methyl-1H-4-oxo- 3-quinolinecarboxylic acid; 1-Cyclopropyl-7- [3 - [(ethylamino] methyl] -1-pyrrolidinyl] -6-fluoro-8-trifluoromethyl-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid; (3-amino-1-pyrrolidinyl) -6-fluoro-1- (2,4-difluorophenyl) -8-trifluoromethyl-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid; 1- (2,4-difluorophenyl) -8-trifluoromethyl-1,4-dihydro-5-methyl-7- (3-methyl-1-piperazinyl) -4-oxo-3-quinolinecarboxylic acid; M 100798 7- [3 - (aminomethyl) -3-methyl-1-pyrrolidinyl] -6-fluoro-1- (2,4-difluorophenyl) -8-trifluoromethyl-1,4-dihydro-5-methyl-4-oxo-3-quinolecarboxylic acid; 7- (3-amino-1-pyrrolidinyl) -1-ethyl-6-fluoro-8-trifluoromethyl-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid; 6-Fluoro-8-trifluoromethyl-1,4-dihydro-5-methyl-7- (3-methyl-1-piperazinyl) -4-oxo-3-quinolinecarboxylic acid; 1-ethyl-6,8- difluoro-1,4-dihydro-5-methyl-4-oxo-7- (1-piperazinyl) -3-quinolinecarboxylic acid, 6.8-difluoro-1- (2,4-difluorophenyl) -1, 4-dihydro-5-yl-methyl-4-oxo-7- (1-piperazinyl) -3-quinolinecarboxylic acid; 6.8-difluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-7- (3,5-dimethyl-1-piperazinyl) -4-oxo-3-quinolinecarboxylic acid; 6-Fluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-4-oxo-7- (1-piperazinyl) -3-quinolinecarboxylic acid and 7- [3- (ethylamino) methyl 1-pyrrolidinyl] -6-fluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid.

Novel intermediates in the preparation of the foregoing compounds include: 1-Cyclopropyl-6,7,8-trifluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid ethyl ester, 2,3,4,5-tetrafluoro-6- methylbenzoyl; Ethyl 3- (2,3,4,5-tetrafluoro-6-methylphenyl) -β-oxopropanoate; ethyl (2,3,4,5-tetrafluoro-6-methylbenzoyl) -3-ethoxy-acrylate; 2- (2,4,5-trifluoro-3-trimethylsilylphenyl) -4,4-dimethyl-2-oxazoline; ethyl-2- (2,3,4,5-tetrafluoro-6-methylbenzoyl) -3-fal-lopropyyliaminoakrylaatti; ι5 100798 2- (2,4,5-trifluoro-6-methyl-3-trimethylsilylphenyl) -4,4-dimethyl-2-oxazoline; 2- (2,4,5-trifluoro-6-methylphenyl) -4,4-dimethyl-2-oxazoline; 2- (3-chloro-2,4,5-trifluoro-6-methylphenyl) -4,4-dimethyl-methyl-2-oxazoline; 2- (3-bromo-2,4,5-trifluoro-6-methylphenyl) -4,4-dimethyl-li-2-oxazoline; 2- (2,4,5-trifluoro-3-hydroxy-6-methyl-phenyl) -4,4-dimethyl-methyl-2-oxazoline; 2- (2,4,5-trifluoro-6-methyl-3-nitrophenyl) -4,4-dimethyl-li-2-oxazoline; 2- (2,4,5-trifluoro-3,6-dimethylphenyl) -4,4-dimethyl-2-oxazoline; 2- [2,4,5-trifluoro-3- (trifluoromethyl) -6-methylphenyl] -4,4-dimethyl-2-oxazoline; 2,6-dichloro-5-fluoro-4-methyl-3-pyridiinikarboksyyli acid; 3-chloro-2,4,5-trifluoro-6-methylbenzoic acid; 3-bromo-2,4,5-trifluoro-6-methylbenzoic acid; 2,4,5-trifluoro-6-methyl-3-nitrobenzoic acid and 2,4,5-trifluoro-3,6-dimethylbenzoic acid.

Compounds of formula I

R3 0

XXJ

r 2 wherein R 1, R 2, R 3, R 4, R 5, R 9, Z, n, R 'and X are as defined above can be prepared by reacting a compound of formula II

R3 O

XXJ

r2 to react with an amine corresponding to group Z, wherein all residues have the same meaning as in formula I above and L is a leaving group which may preferably be fluorine or chlorine.

This invention relates to a process for the preparation of compounds of formula

R

F \ ^ c / COOH

F

wherein R is alkyl, wherein 2-pentafluorophenyl-4,4-dimethyl-2-oxazoline is reacted with an alkyllithium corresponding to the group R to produce a compound of formula

F

followed by acid hydrolysis. compounds of formula it 100798

R

FvJs ^ COOH

B

wherein R is alkyl can be prepared by (a) a compound of formula

X

‘X £ is reacted with a base and trimethylsilyl chloride to give a compound of formula y /

SiMe3 (b) this compound is reacted with a base and an alkyl halide to give a compound of formula

SiMe3 (c) The SiMe3 group is removed and (d) the resulting compound is hydrolyzed.

Naphthyridines of formula I can be prepared (a) by reacting a compound of formula ie 100798 ήΥ-

C ^ N ^ t T

r2 is reacted with oxalyl chloride and dimethylformamide and the reaction is quenched with alcohol to give the corresponding ester of formula JXxJA 'r2 (b) the double bond is reduced to give a compound of formula

C ^ N ^ lT

r2 (c) treating the compound obtained in step (b) with a base,. followed by methyl iodide to prepare an alkylated compound of formula

CH3 o O Cl ^ N ^ tT

; r2 (d) is re-bonded and the resulting naphthyridine is reacted with the desired amine by known methods.

A compound of structural formula I can be readily prepared by treating the corresponding compound of formula II above

19 100798 with the desired cyclic amine defined as Z. For this reaction, the alkylamine substituent of Z may, if desired, be protected with a group which renders it substantially inert under the reaction conditions. Thus, for example, protecting groups such as the following can be used: carboxylacyl groups such as formyl, acetyl, trifluoroacetyl; alkoxycarbonyl groups such as ethoxycarbonyl, tert-butoxycarbonyl, β, β, β-trichloroethoxycarbonyl, β-iodoethoxycarbonyl; aryloxycarbonyl groups such as benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, phenoxycarbonyl; silyl groups such as trimethylsilyl, and groups such as trityl, tetrahydropyranyl, vinyloxycarbonyl, o-nitrophenylsulphenyl, diphenylphosphinyl, p-toluenesulfonyl and benzyl, all of which may be used. If desired, the protecting group may be removed after the reaction between the compounds of formulas II and Z as defined above by methods known to those skilled in the art. For example, the ethoxycarbonyl group can be removed by acid or base hydrolysis and the trityl group can be removed by hydrogenation.

The reaction between a compound of formula II and a suitably protected compound, such as a compound defined as Z, may be carried out with or without a solvent, preferably at elevated temperature for a sufficient time so that the reaction proceeds substantially complete. The reaction is preferably carried out in the presence of an acid acceptor such as an alkali metal or alkaline earth metal carbonate or bicarbonate, a tertiary amine such as triethylamine, pyridine or picoline. Alternatively, an excess of a compound of formula VI may be used as the acid acceptor.

Suitable solvents for this reaction include non-reactive solvents such as acetonitrile, tetrahydrofuran, ethanol, chloroform, dimethyl sulfoxide, dimethylformamide, pyridine, picoline, water and the like. Solvent mixtures can also be used.

Suitable reaction temperatures range from about 20 eC to about 150 eC, with higher temperatures usually requiring shorter reaction times.

Deprotection can be performed either before or after isolation of the product of formula I. Alternatively, the protecting group does not need to be removed at all.

The compounds of formula Z are either known compounds or can be prepared from known starting materials by standard methods or modifications thereof. For example, 3-pyrrolidinemethanamines of formula D

I-N-H

9 ch2nhr3

D

can be readily prepared from a known starting material methyl 5-oxo-1- (phenylmethyl) -3-pyrrolidinecarboxylate, A, [J.Org.Chem., 26, 1519 (1961)] according to the following reaction scheme: 100798, CO 2 CH 3 COHHR 3

I I NH2R3 I I

- A

& E

__CH2NHR3 __ & - 9 H CH2C6H5 Ώ. £

A compound wherein R 3 is hydrogen, i. 3-pyrrolidinemethanamine, disclosed in J. Org. Chem., 26, 4955 (1961).

Thus, compound A can be converted to the corresponding amide B by treatment with R 3 NH 2, for example a saturated solution of ethylamine in an alkanol, for example methyl alcohol. Next, diamide B can be reduced to produce the corresponding diamine C. This reduction can be performed using lithium aluminum hydride, for example, in a conventional solvent such as tetrahydrofuran. Compound C can then be debenzylated, for example using hydrogen and a 20% palladium / carbon catalyst, to produce diamine D. Alternatively, when R in compound C is hydrogen, the primary amine function may be protected with R4, which is as defined above. For example, the primary amine function can be acylated with an acyl halide such as acetyl chloride using well known methods. The primary amine function of compound C can also be converted to a carbamate ester such as ethyl ester by treatment with ethyl chloroformate in the presence of a strong base such as 1,8-diazabicyclo [5.4.0] undec-7-ene in a conventional solvent such as methylene chloride. The benzyl group can then be removed, for example as described above for compound C, to give compound D wherein R is -CO 2 Et, which after being converted to compound Z can be reacted with a compound of formula II to give the corresponding compound of formula I. The group -CO 2 Et can be removed by standard methods.

The syntheses of the starting materials of formula II are described in the following schemes.

23 100798

Scheme 1 shows the preparation of 1-cyclopropyl-6,7,8-trifluoro-1,4-dihydro-5-alkyl-4-oxo-3-quinolinecarboxylic acid.

F N "\ R N— \ ..

^ -

F F

III IV

rrYCOi "i-L FrV'ci ° <C0’G

DMF F ^ V ^ F C0> Et

F F

V VI

° You

F F

VII VIII

R O O R O O

'yW * £ 3 FYVSrA ° Et rV-Ff-V ^ »^"

T A 1A

IX X

R 0 0 f '^ V ^' n F k

XI

24 100798

In Scheme 1 above, 2-Penta-fluorophenyl-4,4-dimethyl-2-oxazoline of formula III is reacted with alkyllithium at -20 ° C to + 25 ° C to give 2- (2.3 (4,5-Tetrafluoro-6-alkylphenyl) -4,4-dimethyl-2-oxazoline, which is hydrolyzed under acidic conditions (preferably by refluxing under cooling with dilute hydrochloric acid), gives the corresponding benzoic acid of formula V. The compound of formula V is reacted with oxalyl chloride and the product is condensed with the dianion of monoethyl malonate (prepared from monoethyl malonic acid and n-butyllithium in THF) to give the keto ester of formula VII. This ketoester is treated with triethyl orthoformate in acetic anhydride to give an adduct of formula VIII. Reaction of a compound of formula VIII with cyclopropylamine in tert-butanol or ether yields an enamine of formula IX, other primary amines can be used in this reaction, such as aliphatic amines (ethylamine, etc.) and aromatic amines (p-fluoroaniline, 2,4- difluoroaniline, etc.). The enamine is reacted with potassium tert-butoxide in dry tert-butanol to form the desired cyclized compound of formula X, which can be hydrolyzed by refluxing in acid to give the compound of formula XI.

25 100798

Scheme 2 depicts the syntheses of 5-alkyl, 8-X-quinolines (X * F).

Il CH3 9 FVVC0? H C1C * CC1 FVSrV ^ SNH— / l ”3 Ä FXX /” t:; · XII CH2Cl2

11 XIII

N "^ N" ^ C

f JL s X · LDA r ___ ji> 1. LDA

Y ^ Y o 2. ClSiMe3 2. Rl step 4

XIV

-JJ & 'JJ & ^ F-JiV ^ F DMF / H2O

SiMe3 100 XVII

XVIII ^ «£ -AT ----- F) W0"

fyS ^ ° * C1 cl A

fJyJLf v

SiMej XVI Nx R R O O

—1 \ »r, j | _HCl_FylyCO, H Γ.1ΑΑ h

"“ °> | \ Pb, oic,. - r \ ^ J

I \ BI B 'A

IfHCll XXI XXII

‘’ In TFA

f F ° H or A

NO, 2.Λ

XXIII XXIV

** r O O (R - H, CH 2) -XUo, F) pAJ 1, - O, H)

XXV

26 100798

In Scheme 2 above, an acid of formula XII is converted to its acid chloride by reaction with oxalyl chloride and the acid chloride is treated with 2-amino-2-methyl-1-propanol N- (2-hydroxy-1,1-dimethylethyl) -2,4,5-tri- to give fluorocarboxamide (a compound of formula XIII). This amide is cyclized to the essential intermediate oxazoline of formula XIV by reaction with thionyl chloride in chloroform. The compound of formula XIV is then treated with a base, preferably lithium diisopropylamide, in THF or ether at -78 ° C and quenched with trimethylsilyl chloride to give the silylated oxazoline of formula XV. The compound of formula XV is treated with a base (again preferably lithium diisopropylamide) in THF or ether at 0-20 ° C, after which the reaction is quenched with alkyl iodide to give, after further work up, the alkylated intermediate of formula XVI. Removal of the trimethylsilyl group is accomplished by treatment with cesium fluoride in aqueous DMF, the resulting compound of formula XVII is hydrolyzed to the corresponding benzoic acid of formula XVIII by refluxing in dilute hydrochloric acid. This benzoic acid is converted to 1-cyclopropyl-6,7-difluoro-1,4-dihydro-5-alkyl-4-oxo-3-quinolinecarboxylic acid using the method previously described in Scheme 1.

Alternatively, the silylated intermediate of formula XVI can be converted to various 3-substituted compounds by an "ipso" reaction on the trimethylsilyl group. For example, a compound of formula XVI is reacted with chlorine in the presence of iron powder, followed by hydrolysis at reflux in dilute acid to give 3-chloro-2,4,5-trifluoro-6-alkylbenzoic acid of formula XIX, which is treated as described above. , to give a quinoline of formula XX. Similarly, an oxazoline of formula XVI is treated with N-bromosuccinimide in chloroform (or pyridinium bromide perbromide in dichloromethane) to give the corresponding 3-bromooxazoline, which is hydrolyzed and prepared to give a compound of formula XXII. Reaction of an intermediate of formula XVI with lead tetraacetate and trifluoroacetic acid followed by acid hydrolysis affords 2,4,5-trifluoro-3-hydroxy-6-alkylbenzoic acid of formula XXIII; the phenol can be converted to the methyl ether by reaction with methyl iodide and potassium carbonate in acetone. This 2,4,5-trifluoro-3-methoxy-6-alkylbenzoic acid is converted to the 8-methoxyquinoline of formula XXIV (where R = CHg), further treatment with HB cleaves off the methyl ether to give the corresponding 8-hydroxyquinoline of formula XXIV (where R = H). Finally, nitration of a silylated compound of formula XVI with nitric acid in sulfuric acid and hydrolysis of the resulting compound affords nitric acid of formula XXV which is further treated to give 1-cyclopropyl-6,7-difluoro-1,4-dihydro-5-alkyl of formula XXVI. 8-nitro-4-oxo-3-quinolinecarboxylic acid (where R 2 = O). Reduction of the nitro group to the amino group can be done using Raney nickel to give a quinoline of formula XXVI (where R1 = H).

28 100798

Scheme 2A shows an alternative method for preparing 5-alkyl, 8-chloroquinolines.

wV 2 'ria fA: Af - ci

xiv XXXVIII

R NnT R

^ il F. Js ^ CO2H

0 If HCl Il KOTEN PREVIOUS · »·

Cl Cl

XXXIX XIX

R O O

F ^ Y ^

ci A

XX

In Scheme 2A above, the oxazoline of formula XIV is treated with a base, preferably lithium diisopropylamide, in THF at -78 ° C and quenched with hexachloroacetone to give the chlorooxazoline of formula XXXVIII. The compound of formula XXXVIII is again treated with a base, preferably lithium diisopropylamide, in THF at 0 ° C and quenched with alkyl iodide to give, after further work-up, an intermediate of formula XXXIX. Hydrolysis of the oxazoline moiety by refluxing in dilute hydrochloric acid affords the benzoic acid of formula XIX. This acid is prepared as 8-chloro-1-cyclopropyl-6,7-difluoro-1,4-dihydro-5-alkyl-4-oxo-3-quinolinecarboxylic acid of formula XX.

30 100798

Scheme 3 depicts the syntheses of 5,8-dialkylquinolines.

N-V * N-trans; Γ FvVLo> 2:

F ^ F

R

XIV XXVII

R 'R' F \ AAo il F ^ X / CC ^ H in the usual way J 0 1 f HCl 1P

F '^' ^ Y ^ F

R R

XXVIII XXIX

R 1 O O wherein R or / and R '= CH 3, Et, F. Js. JL JL propyl.

τΤΊΓοη F '^ rSsN ^ R Ä

XXX

In Scheme 3, an oxazoline of formula XIV (prepared in Scheme 2) is treated with a base, preferably lithium diisopropylamide, in THF at -78 ° C and quenched with an alkyl halide (such as methyl iodide, ethyl iodide, etc.) to give a compound of formula XXVII. a compound wherein R is alkyl. Further treatment with a base (preferably lithium diisopropylamide) in ether at 0 ° C followed by the addition of an alkyl halide gives dialkyloxazolines such as compounds of formula XXVIII. The intermediates are hydrolyzed and worked up as described above to give 5,8-dialkyl-1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid according to formula XXX.

100798 32

Scheme 4 depicts the synthesis of 5-alkylnaphthyridines.

R

Fv / V'C ° 2Et F \ A / CO2Et

Xl ΥΎ

Cl ^ N ^ Al Cl ^ N ^ Cl

XXXI XXXII

o o

Il II

1) C1C-CC1 n 1) Ac2O,

R 2) CO 2 HCl (OEt) 3 1} - [- OK

IIhCl G <CQ2Et 2> A / nH2 2, \ f HCl

Cl ^ N ^ Cl XXXIII

In 30 R = CH 3 'Et' I li II UH propyl.

Cl "'n N

A

XXXIV

OR O O

11 11 U

1) C1C-CC1

Fs / y ^ H 2> F ^ A0> | j —OH SOCl2 j

C ^ N ^ C

XXXV XXXVI

1. RLi or ^ i I f RMgBr Fv ^ kr ^ 0 / U HCl

2 - DDQ I X A JL

Cl N Cl Cl N Cl

XXXVII

XXXIII

33 100798

In Scheme 4 above, a pyridine ester of formula XXXI (Chem.Pharm.Bull. 35 (1987), p. 2280) is reacted with a base such as lithium diisopropylamide in THF at low temperature, followed by reaction with an alkyl halide such as ethyl iodide. or with methyl iodide, hydrolysis of the ester in dilute acid gives a compound of formula XXXIII.

Alternatively, the ester of formula XXXI can be hydrolyzed in dilute acid to give the pyridinic acid of formula XXXV, which in turn is converted to the corresponding oxazoline in the usual manner (see Scheme 2). This oxazoline (a compound of formula XXXVI) is reacted with an alkyllithium (such as methyllithium), after which the compound is re-aromatized with DDQ or chloraniline. This part of the reactions gives the alkyl-substituted pyridine of formula XXXVII, which, after acid hydrolysis, gives the required intermediate of formula XXXIII.

The compound of formula XXXIII is prepared as 5-alkyl-7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid in a conventional manner.

34 100798

Figure 5 - χύ ^

, A 2 A

NaBH3CN

N + CH3 0 0 0 0 ·

F IUI 1] SBULi THF_70C

Cl ^ N ^ nT 2) CH3I Cl ^ N ^ nT

, A 2 A

1) NaH

2) PhSeCl 3) H 2 O 2

CH3 00 NHBOC CH3 0 O

,; * y · 'c: Ay

5 A V, A

nh2 35 100798 Also prepared by this method

CH3 O O

a

B

Ä

In Scheme 5 above, the known naphthyridic acid 1 (U.S. Patent 4,663,457, 1987) is reacted with oxalyl chloride and DMF, after which the reaction is quenched with absolute ethanol to give ester 2. Reduction of the double bond is performed with sodium cyanoborohydride to give compound 3, which is then treated with sec-butyllithium at -78 ° C. This dianion is treated with methyl iodide to give the alkylated intermediate 4. The double bond is re-introduced into the compound by a series of reactions: first treated with sodium hydride, then phenylselenyl chloride is added and oxidized with hydrogen peroxide. The final ester j5 can then be reacted with various amines in the usual manner.

36 100798

Scheme 6 shows the syntheses of 5-alkyl-8-trifluoromethyl derivatives.

1. LDA / THF

~ 78C hf / sf4

2. CO 2 / Et 2 O F 2 J 2 F 120 ° C

84% CO 2 H 8hr · 88% XL 0 0

Il II

o 1. cic-cci o 11 2 ·. CH3 FY ^ Y Γ 1. BUL1 / Et2O FV! ^ R'OH NH2y-CH3 ΛΛ ~ —- AA —— cf3 89% cf3

XLI

XLII

o

f ^ JL xCH3 1. S0C12 F. 1 / 1. LDA

N 2 XV 2 S NH - / - CH 3 2. NaH 2 · RI

f ^^^ a ° H f '^^' f cf3 cf3

XLIII XLIV

R N \ T R 0 O

yyv _ ^ f> iTiiVoh where R = CH3 Ec F'y ^ F F / yNN / CF3 CF3 Ri

XLV XLVI

37 100798

At the beginning of Scheme 6, 2,4,5-trifluorobromobenzene is treated with a base, preferably lithium diisopropylamide, in THF at -78 ° C. This anion reaction is quenched with carbon dioxide to give, after acidification, the acid of formula XL. This acid is reacted with HF / SF4 at 120 ° C to give the trifluoromethyl derivative of formula XLI. The necessary acid functionality is provided by halogen-metal exchange (preferably with butyllithium in ether at -78 ° C), after which the carbon dioxide quenches the reaction and the reaction mixture is acidified. The compound of formula XLII is then treated with oxalyl chloride to form the acid chloride and added to 2-amino-2-methyl-1-propanol in chloroform at 0 ° C to prepare the hydroxyamide of formula XLIII. The cyclization to the key intermediate oxazole of formula XLIX occurs in the usual manner, i. by treatment with thionyl chloride followed by sodium hydride. Deprotection of a compound of formula XLIV with lithium diisopropylamide at -78 ° C and reaction of the anion with an alkyl iodide affords a fully substituted oxazoline of formula XLV which can be prepared to the target quinoline of formula XLVI using previously published methods.

The compounds of formula I are capable of forming pharmaceutically acceptable acid addition and / or base salts. Base salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations include sodium, potassium, magnesium, calcium and the like. Examples of suitable amines are N, N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine and procaine.

Pharmaceutically acceptable acid addition salts are formed with organic and inorganic acids.

38 100798

Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, lemon, oxalic, malonic, salicylic, malic, gluconic, fumaric, succinic, ascorbic, maleic, methanesulfonic acid and the like. The salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce either the mono- or di-salt, etc., in a conventional manner. The free base forms can be obtained again by treating the salt form with a base. For example, aqueous, dilute solutions of bases can be used. Dilute, aqueous solutions of sodium hydroxide, potassium carbonate, ammonia and sodium bicarbonate are suitable for this purpose. The free base forms differ from their corresponding salt forms somewhat in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to their corresponding free base forms for purposes of the invention. Using an excess of a base in which R 'is hydrogen gives the corresponding basic salt.

The compound of formula I may exist in unsolvated as well as solvated forms, including hydrogenated forms. In general, solvated forms, including hydrogenated forms and the like, are equivalent to unsolvated forms for purposes of this invention.

The alkyl groups present in the invention are both straight-chain and branched carbon chains containing 1 to 6 carbon atoms. Typical such groups include methyl, ethyl, propyl, isopropyl and the like.

Cycloalkyl groups are those having 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

Alkoxy groups are both straight-chain and branched carbon chains of 1 to 6 carbon atoms, unless otherwise stated. Typical such groups include methoxy, ethoxy, propoxy, iso-propoxy, tert-butoxy, hexoxy and the like.

The term haloalkyl means halogen-substituted, straight-chain or branched carbon chains having 2 to 4 carbon atoms. One skilled in the art will recognize that a halogen substituent cannot be present on the α-carbon atom of the chain. Typical such groups include β-fluoroethyl, β-chloroethyl, β, β-dichloroethyl, β-chloropropyl, β-chloro-2-propyl, γ-iodobutyl, and the like.

The term halogen means fluorine, chlorine, bromine and iodine unless otherwise stated.

Certain compounds may be in optically active forms. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group.

The compounds of formula I may be prepared and administered in a wide variety of oral and parenteral dosage forms. It will be apparent to those skilled in the art that the following dosage forms may contain as the active ingredient either a compound of formula I or a pharmaceutically acceptable salt of a compound of formula I.

For preparing pharmaceutical compositions from the compounds described in this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders; tablets, disintegrating granules, capsules, starch capsules and suppositories. The solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it may also be an encapsulating agent. In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active compound. In a tablet, the active compound is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. Powders and tablets preferably contain from 5-10% to about 70% of active ingredient. Suitable solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, low melting wax, cocoa butter and the like. The term "preparation" includes a combination of an active compound and an encapsulating material used as a carrier to form a capsule in which the active ingredient (with or without other carriers) is surrounded by a carrier, which is thus in association with the active ingredient. The same goes for starch capsules. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.

Liquid form preparations include solutions, suspensions, and emulsions. Examples are water or aqueous propylene glycol solutions for parenteral injection. Such solutions are prepared in a manner acceptable to biological systems (isotonicity, pH, etc.). Liquid preparations may also be prepared as a solution in aqueous polyethylene glycol solution. Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, e.g. with natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose and other well-known suspending agents.

Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is further subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, for example, packeted tablets, capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these in packaged form.

The amount of active ingredient in a unit dose of the preparation may vary or be adjusted from 1 mg to 100 mg depending on the particular dosage and the potency of the active ingredient.

In therapeutic use in the treatment of bacterial infections, the compounds are used in the pharmaceutical method of the invention by initially administering about 3 mg to about 40 mg per kilogram per day. A daily dose of about 6 mg to about 14 mg per kilogram is preferred.

However, the dosage may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being used. Determining the appropriate dose for a particular situation is within the skill of the art. Generally, treatment is initiated at lower doses that are less than the optimum dose of the compound. Thereafter, the dose is increased in small increments until the optimum effect under these conditions is achieved. For convenience, the total daily dose may be divided and administered during the day, if desired.

The compounds of formula I have antibacterial activity when tested by the microtitration-dilution method described by Heifetz et al. in

Antimicr.Agents & Chemoth., 6, 124 (1974), which is incorporated herein by reference. Using this method, the following lowest inhibitory concentration values (MIC in μg / ml) were obtained for typical compounds of formula I.

42 100798 O) ui _ 4j lo tn ro lt> <ω

CO., LTD. <N LO ι_Π O CM i — I O CM O

• H g OOOi — l ^ fOOi— (OO

[§ Oj oooooooooo> * ω dl o ro m ro ro

4J LO LO O O (N O O

CO OOfHCNOOOOOOO

H g ..........

Ό -h oooooooooo x: σι> i ω O dl o cd 4j ro ro en n o

^ 0) · LO <H O CM O O

H -H g r-10O-ICMCOOOOOO

> Ό -H ..........

O .CO) OOOOOOOOOO

2 -h> n ω

H 4J

(0 CO to

D M

O -P

CO C

M dl dl CM cOcOOOLD CO ro LD ro ro

> 0) - -p O O · - / CM <—I O CM O rH

M C Ή 01 · OOOOOOOOOO

* - »o ε · η ε ..........

E-I At \ Ό-Η OOOOOOOOOO

id Co jz oi <C m 3,> <ω> 2; t0 ω -p o

2 0) H

M 0) S dl «- cd -P ifl in ui ι / i in ui

WC 01 · N N (M O) CM CM LO CM LO

ω -h --h ε OOOOCMOOOOO

E- <C Ό -H ..........

id dl C 01 OOOOOOOOOO

<-H> c Cd CQ Cd

M

E- <2 <

F-I

O CO CM I ΓΟ

• Φ N H H CO ιΟ I> O

O It I CM Is tB OI (M

CM M Is H (M I O | O iH 2> U S QJ CJ <2 «D to S ή 2 <0 to -h tn dl dl dl CO CO (0 -H G dl

dioitö-HOcJja · -ioG

. η3ο · ΗΜβΦα; / οε <ΐ)

0> G <D-Hl-lMu30i • h (T3 OÖityiGGdldlO

ε O-Hg-P3cörat0G> i M ι-l iH 3 -P M »4-1 a D.

• h uodididicnco c UGPaJGGtnt / lcn m V4 a υ υ 3 3 3

cr »dlto tOtflUOCJUU

1-1 -P-H / Ö-H / ÖOOOUCJ

o UXSr-ICJGUCJOOO

rOUi-IGOOOUCJO

-h di di ε »—i» —I o o o

O l-ι -H Ό O> i> i -P -P -P

p ai co-hoää a a a dixJX)> 3ao << i} (Udj

-PUdlOdltOtÖPPP

Gcn.-ipcn.p.p.p-P-P

CdCdidCdP-iCOtncococ /) 43 1 0 0 7 9 8 O) * - ro to ro lo P »- lOiHLOLOOCNr-llOrMLn tn · oooocnooooo • HE ..........

Ό -h oooooooooo x: m

iH W

CD O LO LO

-Pr- 10fMOOOLOCNOOO

en · OOi — IC \ | <NOOCN <—ICM

• HE ..........

• O -H OOOOOOOOOO

xl w> <w <D σ> lo ld lo ro

• p OOOO CM O O O -H

_ «· RHr — I ^ COvDOOt — IOO

<-> -HE -..........

S · 0 · Η OOOOrHOOOOO

M CO

H> r W

>

S O

m'H qjoo lo locolO

jr jX LOCMOOOOOsJOi — I (N

p OOrHrHrtiHOrtOO

g £ [Ö -H OOOOOOOOOO

W C> C W

> CD

M W ^ J_ | ^ | j ^ 8 Έ io ro lo lo

S Tn CNi — iLOOOOfNO CM LO

·. «§. -HE OOOCMCOrHOr-IOO

ω: nj ^ X M OOOOOOOOOO

2 -PO> r ω

H (Λ H

ω ω S

S -H ro ro LO

C e jr r-H i — I100OOCM10100

^ 5. "'G OOOrHCNi — I O O O' —f m pj S en oooooooooo

H ΪΗ W

z <1 — t lo 00 cm l co

CM i — I CO LO I> O

lo i i cm r-- z; en cm

CM K t— <(M I O I

O Z> U S <D O

<Σ i — t W Z Π3 S rH O 'f0 M -H en α> <ι> Γ ~ -ιηωω-Ηβ <υ ODin3rHOa3> —ioc3

fOO-H C 0) <D td E <D

.hu> cs-Hnnoatr 2 «oo cjl aa <u <dog o-HE-Ha (OfO (oc> t -H rH r- (3 PP MH ft ft eoo <u <u <D en tn Λ uccneeaatnenen rn ^ ft -P 0 0 3 3 2 uo λ -m tn ooooo

O -P-HaJtDrtJOOOOO

oä-hhcooooo m o <-h o o o o o o Λ · Η0ωΕ> -Η <-ιοοο o p) -h a o> i> i-p-p-p M CD tn «Ό Ä .3 ftftft

<D, 3.Q + -> 3ftft <D <D <D 4-> OtDO <D (Ö <0PPP Gcnr-tutn + J + J-P-P-P

WUXPh (1 (WMWMM

44 100798 m LO m m p. cn cn m cm

• H g OOr — ICNCOOOCNrHi — I

oooooooooo> h ω <0 CU N * 4-J * -

UJ. ^^ ιΟι-Ηι-IctfiCNlOCOiO

OOrHoOmOOrHOrH

Λ w O iH w «E *

B

> Q) "fl *

jj τ- tO LO

2 O tn · -ho ^^ cdcno ^ · ^^ HH -H -H E ········ ..

4J T3 -H OOOOOOOOOO

cn to x: tn 3> <0> h w

3> P

cn -p m c> qj ai m m en -p · - tn in

M c-Η tn · OOCN ^ cO ^ rHCOiOT-H

E- ^ O £> r ^ £ · ♦ · ♦ ······ 2 ^ \ i3 th oooO' — i o o o · —i n <tn X tn

: tö O,> h W

S> - W: t0

2 -P CJ

h tn M oi (N

«QjS 4-i r- mmoo W in · oocN ^ fcococMi — imin W C -H E ..........

£ h -rH · σ · Ή OOOOrHOOmOCM

K e .e en> —t <CU> h w

PQ -H

M tX

Ep

2 <H

<cO CO CN I m

^ CN rH CO CO I> O

iO i i cn 33 en cn

cn 33 i- <cn I Ο I

O D U Σ 0) U

<Σ rH 33 2 »to S'-η f" to tn -h tn

(Utuc ^ cncnin-HCiu 0) D> f0rHO33rHO3 (OO-H C <U <UC0E <U

u> C2-HPPUCtn • h <oo tn ee <u <uo E O-HE-HC <0 <0 <0C> i cn iH i — t CPP t + HOift: · Ηυοαι <υ <υωω C UCtricOCCcncncn <0 P ft + J uuccc tn <u <o 4-> ιηυυυυυ ρ 4 -> - Ηΐο <υ <οοουου

O CJÄ-HPCCJUOOO

n) υ h οοουυυ and -H <Uwe <HrHooo

O M -H e O> 1> 1 4-3 4-J 4P

P <u tn oj T3 3 t ftcua tutu 4-> υ <υο <υ <ΰ <ορρρ C ω H P W 4-3 4-> 4P 4- * 4-> UM ^ PuCncncncncncn 45 100798

Si ^ «W. N Η 1Λ g OOOCsJ ^ OJt— N '-

2’jj} OOOOOOOOOO

x ω nooLD m en m

7n. H H N 1Λ H m H N

-Hg OOOrHtNCMOOOO

2 ^ OOOOOOOOOO

X w 0

Hb n n in \, and, —I '—I cm

[Fl. 0 <0 <OOCOrHOOC \ Loo

-rHE: ··· .. ··· #.

rQ. ^ oooomooooo x 0 X w o u Ä (l) l · t-ι + j · <- cn m I— (w. m m m <—i cm m

p., Hg OOrHCMOOOOrHOO

05 -H ..........

Z o .ccn oooooooooo

M -H X W

4-) ω m jq O 0 ω r- ~ o u x> * - co 4- »0 · mm

M C -HE 2 CNCOOiDfHOCOOrH

> 0 0S -H ..........

H 01 XU) OOOiHrHOOOOO

M C Ή X W

El O E

Z Λ! \ <C CD 0: 0 O 0 r- ~ m Z> - 4-), - cm m

W: 0 01 · C \ | rHrfCOiOrHO0 <OrH

Z 4J U -HE * .........

Η 01 Μ Ό-Η OOOOr — IOOOOO

02 0 2 -C 0 ω x w ω c E-I Ή ti C 0 t "<0 4-> * - m cq -η oi · m m cm m

H & <-HE OOrHCMCOrHOCMOrH

E-ι 03 -H ..........

Z XU) OOOOOOOOOO

., <c x w

I-h

o co es I m

CM rH CO ιΟ I> O

VO I I CM r- w CO CM

CM P3 · —t CM I O I

oz> u 2 0 u <2 rH KD 0 2 rH Γ "0 03 -EN) 00r ^ www-HC0 0tJl0rHO33rHOC * .0O-HC000E0 U> G2-HH * -io3cn ^ 000133000 S O-HE-H 3000G> iu ) γΗγη3μμ ή aa HUO 0 0 0 03 03 C UOO> 0330W0 0 UQ «-P υ Ό 3 0 3 cr> 00 -Ροιυυυυο

M + -) - H 000OOUUU

O OXJrHVHCUUOOO

0 o rH οοουυυ Λ-Η0ΜΕ - ΗΙ-ΗΟΟΟ O 0 -H 3 o> 1> 1 +3 4) +) Ιη00003Χ2χ2Ο <Ο <Ρ <0 4U -Q 4-) O 0.0.0 0 0 4-> U0O0005hMO βωΓΗθω4-> 4-) 4 -) - Ρ-Ρ (43UXPH (Xitococ / 3mm 46 100798

The following non-limiting examples illustrate preferred methods for preparing the compounds described above.

Preparation of starting materials

Example A

2- (2,3,4,5-tetrafluoro-6-methylphenyl) -4,4-dimethyl-2-oxazoline

A solution of 21.2 g (80.0 mmol) of 2- (pentafluorophenyl) -4,4-dimethyl-2-oxazoline (Bull.Chem.Soc. Jpn., 57, 225 (1984)) in 300 ml in dry ether, cooled to -20 ° C under argon and treated with 60 mL of 1.6 M methyllithium (96.0 mmol). The solution was stirred at -20 ° C for two hours, then stirred at room temperature overnight. The mixture was diluted with water and the organic layer was dried over magnesium sulfate and concentrated to give 20.8 g of the title compound as an orange oil.

Example B

2,3,4,5-tetrafluoro-6-metyyllbentsoehappo

A mixture of 20.5 g (73.4 mmol) of 2- (2,3,4,5-tetrafluoro-6-methylphenyl) -4,4-dimethyl-2-oxazoline in 200 ml of 6 N hydrochloric acid , was refluxed for 18 hours, then cooled to room temperature. The solution was extracted with ethyl acetate. The extract was washed with water, dried over magnesium sulfate and concentrated. The residue was suspended in water which was basified (pH 11) with 1 M sodium hydroxide and extracted with ether, the aqueous phase acidified (pH 2) with 1N hydrochloric acid and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and concentrated to give 8.4 g of the title compound as a tan solid, m.p. was 80-82 ° C.

47 100798

Example C

2,3,4 / 5-tetrafluorl-6-metyyllbentsoyyllkloridi

A solution of 8.2 g (39.4 mmol) of 2,3,4,5-tetrafluoro-6-methylbenzoic acid, 6.0 g (47.2 mmol) of oxalyl chloride and 100 ml of dichloromethane was treated with three drops of DMF was added. The solution was stirred for 3 hours, after which it was concentrated to give 8.8 g of the title compound as a yellow liquid. The product was used as such in the next step.

Example D

Ethyl-3- (2,3,4,5-tetrafluoro-6-metyvllfenyyll) -β-oxo-propanoaattl

A solution of 10 g (76.5 mmol) of malonic acid monoethyl ester bipyridyl (catalytic) and 200 mL of dry THF was cooled to -35 ° C under argon, treated with 52 mL of 1.5 M n-butyllithium ( 78 mmol) and warmed to -5 ° C. To this mixture was added 52 mL of 1.5 M n-butyllithium (78 mmol) until a pale pink color persisted for 10 minutes. The suspension was cooled to -78 ° C and treated with a solution of 8.8 g (38.8 mmol) of 2,3,4,5-tetrafluoro-6-methylbenzoyl chloride in 100 mL of dry THF. The reaction mixture was stirred at -78 ° C for 45 minutes, after which it was warmed to -35 ° C and poured into a mixture of ice and 1N hydrochloric acid (77 ml). The organic layer was washed with 5% sodium bicarbonate solution, 3M hydrochloric acid and water and dried over magnesium sulfate. Concentration gave an orange oil which was chromatographed on silica gel (E. Merck 230-400 Mesh) eluting with a 80:20 mixture of chloroform and ethyl acetate to give 8.2 g of the title compound.

«100798

Example E

Ethyl-2- (2,3,4,5-tetrafluoro-6-methylbenzoyl) -3-etokslakrylaatti

A solution of 8.1 g (29.1 mmol) of ethyl 3- (2,3,4,5-tetrafluoro-6-methylphenyl) -p-oxopropanoate, 7.2 g (43.3 mmol) triethyl orthoformate and 70 ml of acetic anhydride, refluxed for 3.5 hours. The solution was cooled to room temperature and concentrated under high vacuum to give 9.1 g of the title compound. The product was used as such in the next step

Example F

Ethyl-2- (2,3,4,5-tetrafluoro-6-methylbenzoyl) -3-cyclopropylaminoacrylate

To a solution of 9.0 g (27.0 mmol) of ethyl 2- (2,3,4,5-tetrafluoro-6-methylbenzoyl) -3-ethoxyacrylate in 30 ml of absolute ethanol at 5 ° C , 1.68 g (29.4 mmol) of cyclopropylamine were added. The mixture was stirred at 5 ° C for 1.5 hours and at room temperature for 2.5 hours. The solution was concentrated to an oil which was triturated with hexane to give a tan solid. The crude product was recrystallized from hexane to give 9.07 g of the title compound, m.p. was 72-74 ° C.

Example G

Ethyl 1-cyclopropyl-6,7,8-trifluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylate

To a mixture of 9.05 g (26.3 mmol) of ethyl 2- (2,3,4,5-tetrafluoro-6-methylbenzoyl) -3-cyclopropylaminoacrylate in 100 ml of dry tert-butanol was added a slurry of 3.25 g (29.0 mmol) of potassium tert-butoxide in 20 ml of dry tert-butanol, and the mixture was stirred at 60 ° C for 4 hours. The suspension was cooled to 49,100798 room temperature and concentrated to a paste which was partitioned between dichloromethane and 1N hydrochloric acid. The organic layer was separated, dried over magnesium sulfate and concentrated. Recrystallization from a mixture of ethyl acetate and hexane gave 4.70 g of the title compound, m.p. was 176-177 ° C.

Example H

l-cyclopropyl-6,7,8-trifluoro-l, 4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid

A mixture of 4.6 g (14.1 mmol) of ethyl 1-cyclopropyl-6,7,8-trifluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylate 100 in 6 M hydrochloric acid, refluxed for 4 hours. The solution was cooled to room temperature and the solids were filtered, washed with water and dried to give 3.9 g of the title compound, m.p. was 234-235 eC.

In a similar manner, 1-cyclopropyl-5-ethyl-6,7,8-trifluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid and 1,5-dicyclopropyl-6,7,8-trifluoro-1 , 4-dihydro-4-oxo-3-quinolinecarboxylic acid.

Example I

N- (2-hydroxy-l, l-dimethylethyl) -2,4,5-trifluorl-bentsamldl

A solution of 19.4 g (110 mmol) of 2,4,5-trifluorobenzoic acid (JP 58,150,543 (Cl. C07C69) Sep. 7, 1983), 15.2 g (120 mmol) of oxalyl chloride and 250 ml of dichloromethane was treated with 4 drops of DMF and the mixture was stirred at room temperature for 4 hours. The mixture was concentrated to an oil and redissolved in 100 mL of dichloromethane. This solution was added dropwise to a solution of 19.6 g (240 mmol) of 3-amino-2-methyl-1-propanol in 200 ml of dichloromethane at 5 ° C, and the reaction mixture was stirred at 100 ° C at room temperature overnight. The solids were filtered and the filtrate was washed with 5% sodium bicarbonate, 1 N hydrochloric acid and water. The organic layer was dried over magnesium sulfate and concentrated to give 24.5 g of the title compound, m.p. was 114-116 ° C.

Example J

2- (2,4,5-trlfluorifenyyli) -4,4-dimethyl-2-oxazoline

To a solution of 24.4 g (98.7 mmol) of N- (2-hydroxy-1,1-dimethylethyl) -2,4,5-trifluorocarboxamide in 200 mL of chloroform was added dropwise 25 mL (342 mmol) of thionyl chloride. . The solution was stirred overnight at room temperature, then concentrated to half volume. The mixture was diluted with ether and the solid was removed by filtration. This solid was dissolved in water, basified (pH 8) with 10% sodium hydroxide and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and concentrated to give 19.0 g of the title compound, m.p. was 53-54 ° C.

Example K

2- (2,4,5-trlfluori-3-trimetyyllsllyylifenyyli) -4,4-dimethyl-2-oxazoline

A solution of 8.7 mL (62.1 mmol) of diisopropylamine in 100 mL of dry THF under argon was cooled to -78 ° C and treated with 28.3 mL (56.6 mmol) of 2 .0 M n-butyllithium. The LDA solution was stirred at -78 ° C for 15 minutes. To this solution was added a solution of 11.8 g (51.5 mmol) of 2- (2,4,5-trifluorophenyl) -4,4-dimethyl-2-oxazoline in 50 mL of THF and the reaction mixture. stirred for one hour at -78 ° C. To the reaction mixture was added 13 ml (102.5 mmol) of chlorotrimethylsilane, and the solution was warmed to room temperature. Water was added, the organic layer was dried over magnesium sulfate and concentrated. The crude product was chromatographed on silica gel (E.Merck 230-400 Mesh) eluting with a 80:20 mixture of chloroform and ethyl acetate to give 12.9 g of the title compound, m.p. was 71-72 ° C.

Example L

2- (2,4,5-Trifluoro-6-methyl-3-trimethylsilylphenyl) -4,4-dimethyl-2-oxazoline

A solution of 0.64 mL (4.57 mmol) of diisopropylamine in 20 mL of dry THF under argon was cooled to -78 ° C and treated with 2.1 mL (4.20 mmol) of 2 .0 N n-butyllithium. The LDA solution was stirred at -78 ° C for 15 minutes, then warmed to 0 ° C. To this solution was added a solution of 1.05 g (3.5 mmol) of 2- (2,4,5-trifluoro-3-trimethylsilylphenyl) -4,4-dimethyl-2-oxazoline in 5 mL of THF: The reaction mixture was stirred at 0 ° C for 45 minutes, after which the reaction was quenched with 1.50 g (10.6 mmol) of methyl iodide. The solution was stirred at room temperature for 3 hours and diluted with water. The organic layer was washed with water, dried over magnesium sulfate and concentrated to give 1.00 g of the title compound as an oil.

In a similar manner, 1-cyclopropyl-5-ethyl-6,7-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid and 1-cyclopropyl-6,7-difluoro-1,4-dihydro-4 oxo-5-iso-propyl-3-quinolinecarboxylic acid.

Alternatively, the trimethylsilyl group was replaced with chlorine (Chem. Abstr. 54, 20932 (1960)) or bromine (J. Am. Chem. Soc. 70, 433 (1948)) and the oxazoline was hydrolyzed to give 3-chloro-2,4,5- trifluoro-6-methylbenzoic acid and 3-bromo-2,4,5-trifluoro-6-methylbenzoic acid, respectively. From these intermediates, 8-chloro-1-cyclopropyl-6,7-difluoro-1,4-dihydro-5-methyl-4-52 100798 oxo-3-quinolinecarboxylic acid, 8-bromo-1-cyclopropyl-6,7 difluoro-l, 4-dihydro-5-methyl-4-oxo-3-kinoliinikar-acid.

In addition, the trimethylsilyl group was reacted with lithium tetraacetate / trifluoroacetic acid to add a hydroxyl group (Tet.Lett. 10, 853 (1974)) and was also reacted with nitric acid to add a nitro group (J. Chem. Soc. 498 (1957)).

Using conventional methods, the following compounds were prepared: 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-hydroxy-5-methyl-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-5-methyl-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6,7-difluoro-1,4-dihydro-5-methyl-8-nitro-4-oxo-3-quinolinecarboxylic acid and 8-amino-1-cyclopropyl-6,7-difluoro-1, 4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid.

Example M

7-Chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid

Ethyl 2,6-dichloro-5-fluoronicotinate (Chem. Pharm. Bull, 2 (6), 2280 (1987)) was treated with lithium diisopropylamide and quenched with methyl iodide to give, after further work-up, ethyl 2,6-dichloropropylamide. -dichloro-5-fluoro-4-methylnicotinate. This compound was hydrolyzed to give the corresponding acid, which was worked up in the usual manner to give 7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-1,8-naphthyridine-3- carboxylic acid. In a similar manner, 7-chloro-1-cyclopropyl-5-ethyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid was synthesized.

»100798

Example N

2,4,5-Trifluoro-3,6-dimethylbenzoic acid 2- (2,4,5-trifluorophenyl) -4,4-dimethyl-2-oxazoline was also treated with lithium diisopropylamide followed by methyl iodide to give 2- (2, 4,5-trifluoro-3-methyl-phenyl) -4,4-dimethyl-2-oxazoline. This intermediate was in turn treated with lithium diisopropylamide followed by methyl iodide to give 2- (2,4,5-trifluoro-3,6-dimethylphenyl) -4,4-dimethyl-2-oxazoline. Hydrolysis of oxazoline afforded 2,4,5-trifluoro-3,6-dimethyl-benzoic acid which was converted to 1-cyclopropyl-6,7-difluoro-1,4-dihydro-5,8-dimethyl-4-oxo -3-quinolinecarboxylic acid as usual.

Example O

2- (2,4,5-trlfluori-6-methylphenyl) -4,4-dimethyl-2-oksatsolllnl

A solution of 12.0 g (38.0 mmol) of 2- [2,4,5-trifluoro-6-methyl-3- (trimethylsilyl) phenyl] -4,4-dimethyl-2-oxazoline, 5 , 85 g (38.5 mmol) of cesium fluoride, 110 ml of dimethylformamide and 15 ml of water were stirred for 18 hours at room temperature. The reaction mixture was poured into water and extracted with ethyl acetate, the organic phase was washed with water, dried over magnesium sulfate and concentrated to give 9.1 g of a liquid.

Example P

2- (3-chloro-2,4,5-trifluorophenyl) -4,4-dimethyl-2-oxazoline

A solution of 7.6 mL (54.2 mmol) of diisopropylamine in 100 mL of dry THF was cooled to -78 ° C under argon and treated with 20.5 mL (47.2 mmol) of 2.3 M n-butyllithium and stirred for 15 minutes. To this solution was added a solution of 10.3 g (45.0 54 100798 mmol) of 2- (2,4,5-trifluorophenyl) -4,4-dimethyl-2-oxazoline in 100 mL of dry THF. . The reaction mixture was stirred at -78 ° C for 45 minutes. To this mixture was added 26.5 g (100 mmol) of hexachloroacetone and the solution was warmed to room temperature. Water was added, the organic phase was washed with water, 1N hydrochloric acid and 5% sodium bicarbonate and dried over magnesium sulfate. Concentration gave a dark oil which was chromatographed on silica gel to give 7.05 g of the title compound as a yellow oil.

Example Q

2- (3-chloro-2,4,5-trlfluori-6-methyl-4,4-dimethyl-2-oxazoline

A solution of 5.5 mL (39.2 mmol) of diisopropylamine in 125 mL of dry THF was cooled to -78 ° C under argon and treated with 13.8 mL (31.7 mmol). 2.3 M n-butyllithium and stirred for 15 minutes. To this solution was added a solution of 7.00 g (26.5 mmol) of 2- (3-chloro-2,4,5-trifluorophenyl) -4,4-dimethyl-2-oxazoline in 75 mL of dry THF. was added. The mixture was stirred at -78 ° C for 30 minutes and at 0 ° C for 60 minutes. To this solution was added 11.3 g (79.6 mmol) of methyl iodide, and the mixture was stirred at room temperature overnight. Water was added, the organic phase was washed with 1 N HCl, 5% sodium bicarbonate and water. The solution was dried over magnesium sulfate and concentrated to an oil which was chromatographed on silica gel to give 6.3 g of a clear orange oil.

<

Example R

2,4,5-trifluoro-6-methylbenzoic acid

A mixture of 9.1 g (37.4 mmol) of 2- (2,4,5-trifluoro-6-methylphenyl) -4,4-dimethyl-2-oxazoline in 200 ml of 6 M hydrochloric acid was refluxed overnight. 55 100798, after which it was cooled to room temperature. The solution was extracted with ethyl acetate, and the extract was washed with water, dried over magnesium sulfate and concentrated. The residue was suspended in water which was basified (pH 11) with 1 N NaOH, washed with ether and acidified (pH 2) with 1N H 2 O. The solution was extracted with ethyl acetate. The organic phase was washed with water, dried over magnesium sulfate and concentrated to give 5.8 g of the title compound, m.p. was 108-110 ° C.

Example S

3-chloro-2,4,5-trlfluorl-6-metyvllbentsoehappo

As described in Example D, the title compound was prepared from 2- (3-chloro-2,4,5-trifluoro-6-methylphenyl) -4,4-dimethyl-2-oxazoline and 6 N hydrochloric acid. The desired acid was obtained as a tan solid, m.p. was 104-106 eC.

Example T

2,4,5-trifluorl-6-metyylibentsoyyliklorldl

A solution of 5.8 g (30.5 mmol) of 2,4,5-trifluoro-6-methylbenzoic acid, 4.7 g (37.0 mmol) of oxalyl chloride and 100 ml of dichloromethane was treated with three drops of DMF. . The reaction mixture was stirred at room temperature for 2 hours, after which it was concentrated to give 6.3 g of the title compound as an oily solid. The product was used "as is" in the next step.

Example U

3-Chloro-2,4, S-trifluorl-e metyylibentsoyyliklorldl

The title compound was prepared from 3-chloro-2,4,5-trifluoro-6-methylbenzoic acid and oxalyl chloride following the procedure described in Example F.

56 100798

Example V

Ethyl-3- (2,4,5-trifluorl-6-methylbenzoyl) -β-oxo-propanoaattl

A solution of 8.0 g (60.5 mmol) of malonic acid monoethyl ester bipyridyl (catalytic) and 200 mL of dry THF was cooled to -35 ° C under argon and treated with 32 mL of 1.9 M n- butyllithium (60.8 mmol) and warmed to -5 ° C. To this suspension was added an additional 32 mL of 1.9 M n-butyllithium until a pale pink color persisted for 10 minutes. The mixture was cooled to -78 ° C. To this mixture was added a solution of 6.3 g (30.2 mmol) of 2,4,5-trifluoro-6-methylbenzoyl chloride in 75 mL of dry THF, and the reaction mixture was stirred at -78 ° C for one hour. . The solution was then warmed to -35 ° C, poured into a mixture of ice and 1N hydrochloric acid (70 ml) and extracted with ethyl acetate. The organic layer was washed with 5% sodium bicarbonate, 3 M hydrochloric acid and water and mixed with magnesium sulfate. Concentration gave an oil which was chromatographed on silica gel (E.Merck 230-400 Mesh) eluting with a 80:20 mixture of chloroform and ethyl acetate to give 7.2 g of the title compound.

Example W

Ethyl-3- (3-chloro-2,4,5-trifluoro-6-methylbenzoyl) -β-oxopropanoate

The procedure set forth in Example H was used to prepare the title compound from the dianion of a monoethyl ester of malonic acid and 3-chloro-2,4,5-trifluoro-6-methylbenzoyl chloride. The crude product was also chromatographed on silica gel to give the desired product as an orange oil.

* 57 100798

Example X

Ethyl-2- (2,4,5-trlfluorl-6-metvyllbentsoyyll) -3-ethoxy-akrylaattl

A solution of 7.1 g (27 mmol) of ethyl 3- (2,4,5-trifluoro-6-methylbenzoyl) -3-oxopropanoate, 6.8 g (41 mmol) of triethyl orthoformate and 60 ml of acetic anhydride ride, refluxed for 3 hours, cooled to room temperature and concentrated to give 8.4 g of the title compound. The crude product was used as such in the next step.

Example Y

Ethyl 2- (3-chloro-2,4,5-trifluoro-6-methylbenzoyl) -3-ethoxyacrylate

Using the procedure set forth in Example J, the title compound was prepared from ethyl 3- (3-chloro-2,4,5-trifluoro-6-methylbenzoyl) -β-oxopropanoate, triethyl orthoformate and acetic anhydride.

Example Z

Ethyl-2- (2,4,5-trifluoro-6-metvvllbentsoyyli) -3-cyclo-propyyliaminoakrylaattl

To a solution of 8.3 g (26 mmol) of ethyl 2- (2,4,5-trifluoro-6-methylbenzoyl) -3-ethoxyacrylate in 30 ml of absolute ethanol at 5 ° C was added 1.64 g (29 mmol) cyclopropylamine. The reaction mixture was stirred at 5 ° C for 90 minutes and at room temperature for 2 hours.

*. The solution was concentrated to give a brown oil which was dissolved in hexane and reconcentrated to give a tan solid. Recrystallization from hexane gave 7.2 g of colorless crystals of m.p. was 69-72 ° C.

58 100798

The following compounds were prepared in a similar manner from the appropriate ethoxyacrylate: a) ethyl 2- (3-chloro-2,4,5-trifluoro-6-methylbenzoyl) -3-cyclopropylaminoacrylate, m.p. 77-80 ° C; b) ethyl 2- (2,3,4,5-tetrafluoro-6-methylbenzoyl) -3-ethylaminoacrylate, hygroscopic solid; c) ethyl 3- (2,4-difluoroanilino) -2- (2,3,4,5-tetrafluoro-6-methylbenzoyl) acrylate, viscous oil; d) ethyl 3- (2-bromoethylamino) -2- (2,3,4,5-tetrafluoro-6-methylbenzoyl) acrylate, m.p. 95-100 ° C; e) ethyl 3- (ethylamino) -2- (2,4,5-trifluoro-6-methylbenzoyl) acrylate, hygroscopic solid; f) ethyl 3- (2,4-difluorlanilino) -2- (2,4,5-trifluoro-6-methylbenzoyl) acrylate, m.p. 79-83 ° C and g) ethyl 3- (2-bromoethylamino) -2- (2,4,5-trifluoro-6-methylbenzoyl) acrylate.

Example AA

Ethyl l-cyclopropyl-6,7-difluoro-l, 4-dihydro-4-oxo-3-kinollinikarboksylaatti

A solution of 7.2 g (22 mmol) of ethyl 2- (2,4,5-trifluoro-5-methylbenzoyl) -3-cyclopropylaminoacrylate in 100 ml of dry tert-butanol was treated portionwise with 2 portions. , 8 g (25 mmol) of potassium tert-butoxide and the reaction mixture were stirred at 60 ° C for 5 hours. The suspension was cooled to room temperature and concentrated. The residue was partitioned between dichloromethane and 1N hydrochloric acid, the organic phase was washed with water, dried over magnesium sulfate and concentrated. The crude product was slurried in boiling ethanol, filtered and air dried to give 4.2 g of the title compound.

The following compounds were prepared in the same manner and purified as indicated: a) ethyl 8-chloro-1-cyclopropyl-6,7-difluoro-1,4-difluoro-1,4-dihydro-5-methyl-4-oxo- 3-Quinolinecarboxylate, 100798 59, m.p. 151-153 ° C (chromatographed on silica gel); b) ethyl 1-ethyl-6,7,8-trifluoro-1,4-dihydro-5-methyl-4-oxo-3-chlorocarbonyl carboxylate / m.p. 185-187 ° C (recrystallized from ethyl acetate); c) ethyl 1- (2-bromoethyl) -6,7,8-trifluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylate, m.p. 149-150 ° C (recrystallized from ethyl acetate / hexane); d) ethyl 1-ethyl-6,7-difluoro-1,4-dihydro-5-methyl-4-oxo-3-chlorolinecarboxylate, m.p. 189-191 eC.

Example BB

Ethyl-6,7,8-trlfluori-l, 4-dihydro-5-methyl-4-oxo-l-vinyl-3-klnolllnlkarboksylaattl

A rapidly stirred suspension of 1.98 g (5.08 mmol) of ethyl 1- (2-bromoethyl) -6,7,8-trifluoro-1,4-dihydro-5-methyl-4-oxo- 3-Quinolinecarboxylate, 3.50 g (25.3 mmol) of ground potassium carbonate and 40 mL of DMF was heated at 80 ° C under argon for 4 hours. The suspension was concentrated and the residue partitioned between methylene chloride and water. The organic layer was dried over magnesium sulfate and concentrated to give 1.52 g of the title compound as a DMF complex, m.p. was 150-152 eC.

Example CC

Ethyl 6,7,8-trifluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylate

To a cold (5 ° C) solution of 2.77 g (6.64 mmol) of ethyl 3- (2,4-difluoroanilino) -2- (2,3,4,5-tetrafluoro-6-methylbenzoyl) acrylate 60 in 1 ml of dry THF, 0.32 g of 60% sodium hydride was added. The solution was stirred overnight at room temperature, after which it was concentrated to an orange foam. The residue was partitioned between methylene chloride and 1 N HCl. The organic phase was washed with water, dried over magnesium sulfate and concentrated to an orange solid which was recrystallized (from ethyl acetate / hexane) to give 1.55 g of the title compound, m.p. was 152-154 ° C.

Example DD

Ethyl 6,7-difluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylate The procedure described in Example AA was used to prepare the title compound from ethyl 3- (2 , 4-difluoroanilino) -2- (2,4,5-trifluoro-6-methylbenzoyl) acrylate, m.p. was 161-164 ° C.

Example EE

l-cyclopropyl-6,7-difluoro-l, 4-dihydro-4-oxo-3-kinolilnlkarboksyylihappo

A suspension of 4.1 g (13.3 mmol) of ethyl 1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylate in 150 ml of 6N hydrochloric acid was boiled. at reflux for 6 hours, then cooled to room temperature. The solids were filtered, washed with water and ether and dried to give 3.2 g of the title compound, m.p. was> 300 eC.

The following compounds were prepared in a similar manner: a) 1-ethyl-6,7-8-trifluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid, m.p. 199-201 ° C; b) 1-ethyl-6,7-difluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolecarboxylic acid, m.p. > 300 eC; c) 8-chloro-1-cyclopropyl-6,7-difluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid, m.p. 212 -214 eC.

no 100798

Example FF

7-Chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid ethyl ester 7-Chloro-1-cyclopropyl-6-fluoro-1,4-dihydro- 4-Oxo-1,8-naphthyridine-3-carboxylic acid (U.S. Patent 4,663,457) (20.0 g, 71 mmol) and dimethylformamide (0.5 mL) were added to dichloromethane (750 mL) to give a tan slurry. To this slurry was added oxalyl chloride (7.4 mL, 85 mmol) over one minute and the reaction mixture was stirred for 90 minutes, after which an additional 2.0 mL of oxalyl chloride was added and stirring was continued for 60 minutes. To the resulting brown solution was added absolute ethanol (4.3 mL, 78 mmol) and the mixture was stirred for 4 h, then cooled to 0 ° C and stored overnight. The reaction mixture was warmed to room temperature and an additional 2 mL of absolute ethanol was added and stirring was continued for 3 hours. The reaction mixture was evaporated to a brown solid. The solid was heated in THF, filtered and cooled to 0 ° C. The formed crystals were collected and dried to give the title compound (11.1 g, 50%).

Example GG

7-Chloro-1-cyclopropyl-6-fluoro-1,2,3,4-tetrahydro-4-oxo-1,8-naphthyridine-3-carboxylic acid ethyl ester, 3

The compound prepared in Example FF (3.0 g, 9.6 mmol) and sodium cyanoborohydride (0.7 g, 10 mmol) were suspended in absolute ethanol (200 mL) and 3 drops of concentrated HCl were added to give a bright yellow solid. Liu os. The reaction proceeded and was monitored by TLC (silica gel, CH 2 Cl 2 / CH 3 OH, 9: 1, v / v), if necessary concentrated HCl was added to maintain the progress of the reaction. After 6 hours, the reaction was quenched by adding it to 300 mL of water. The reaction mixture was extracted several times with CH 2 Cl 2 and the combined organic layers were dried, filtered and evaporated to a yellow solid. This solid was filtered through silica gel with CH 2 Cl 2 and after evaporation the solid was crystallized from isopropyl ether. The collected crystals were further purified by column chromatography on silica gel, eluting with CH 2 Cl 2 to give the title compound (2.2 g, 73%).

The following compound was prepared in a similar manner: a) 7-Chloro-6-fluoro-1- (2,4-difluoro-phenyl) -1,2,3,4-tetrahydro-4-oxo-1,8-naphthyridine-3-carboxylic acid ethyl ester .

Example HH

7-Chloro-1-cyclopropyl-6-fluoro-1,2,3,4-tetrahydro-5-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid ethyl ester

Compound GG (4.5 g, 14 mmol) was dissolved in THF (170 mL) and cooled to <-70 ° C. Then, sec-butyllithium (22.2 mL, 28 mmol, 1.3 M) was added dropwise over 30 minutes. , the internal temperature was kept <-70 ° C. The mixture was stirred at -70 ° C for 1 hour, then methyl iodide (0.9 ml, 14 mmol) was added and the reaction mixture was stirred at -70 ° C for 7 hours. at dry ice / isopropanol and allowed to stand for 17 h At the end of this period, the reaction temperature had risen to -25 [deg.] C. The reaction was quenched by the addition of saturated NH4Cl solution (50 mL) and the reaction mixture was diluted with an equal volume of: CH2Cl2. separated and washed with saturated NaCl solution, dried, filtered and evaporated to an oil, which was purified by column chromatography on silica gel, eluting with CH2Cl2 to give the appropriate fractions combined and evaporated. after, the title compound (3.91 g, 85%).

63 100798

Example II

7-Chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-1,8-naphthyridin-3-carboxylic acid ethyl ester Using the method of Reich et al., J. Amer. Chem. Soc., (1975) 97, 5434, the compound prepared in Example HH (0.68 g, 2.1 mmol) was converted to the title compound (0.44 g, 64%). Purification was performed by crystallization from isopropyl ether.

Example JJ

3-bromo-2,5,6, -trifluoribentsoehappo

To a solution of diisopropylamine (8.89 g, 88 mmol) in THF (80 mL) stirred under nitrogen at 0 ° C was added n-butyllithium (2.6 M in hexane, 32 mL) over 10 minutes. , 84 mmol). After 10 minutes at 0 ° C, the solution was transferred by catheter over 40 minutes to a solution of 2,4,5-trifluorobromobenzene (16.88 g, 80 mmol) in THF (200 mL) and stirred under nitrogen at -78 ° C. :in. After 15 minutes, the solution was blown through the catheter over about 2 minutes into a slurry of CO 2 (about 200 mL) in ether (400 mL) with vigorous stirring. After CO 2 evaporated, the slurry was washed with dilute HCl (1 M, 200 mL) and water (100 mL). The organic phase was extracted with dilute NaOH (0.5 M, 2 x 100 mL). The aqueous phase was extracted with ether (2 x 100 mL) and the combined organic phases were washed with water (100 mL), brine (100 mL) and dried (MgSO 4). Solvent: removed under reduced pressure to give 3-bromo-2,5,6-trifluorobenzoic acid (17.25 g, 84.5%) as white microcrystalline needles, m.p. was 114-116 eC (sublimed).

64 100798

Example KK

1-Bromo-2,4 / 5-trifluoro-3- (trifluoromethyl) benzene-3-bromo-2,5,6-trifluorobenzoic acid (16.92 g, 66 mmol) was heated under SF 4 (60 g) and HF. (30 g) in a stainless steel bomb at 120 ° C for 8 hours. After the reaction mixture was cooled to 25 ° C, the volatiles were removed through KOH locks, and when gas evolution ceased, the vessel was extracted with CH 2 Cl 2 (150 mL). This solution was washed with dilute NaHCO 3 solution (sat. / 2, 50 mL), brine (50 mL) and dried (MgSO 4). The solvent was removed by distillation through a 15 can Vigreux column and the residue was distilled under a nitrogen atmosphere through a short distillation column at 147-150 ° C to give 1-bromo-2,4,5-trifluoro-3- (trifluoromethyl) benzene (15 , 79 g, 83%) as a pale yellow oil.

NMR (CDCl 3): 67.67 (1H, t of d, Jd = 6 Hz, Jt = 8.1 Hz, aromatic).

Example LL

2,4,5-Trifluoro-3- (trifluoromethyl) benzoic acid

A solution of n-butyllithium (2.6 M in hexane, 9.6 mL, 25 mmol) was added dropwise via addition funnel over 15 minutes to a solution of 1-bromo-2,4,5-trifluoro-3- (trifluoromethyl) benzene (7.00 g, 25 mmol) in ether (100 mL) and stirred under a nitrogen atmosphere at -78 ° C. After 5 minutes, the mixture was rapidly blown catheter into a suspension of dry ice (100 g) in ether (100 mL). After 5 minutes, TFA (2 mL) was added to this solution. After warming to 20 ° C, the solution was washed with dilute HCl (0.5 M, 20 mL) and extracted with dilute base (0.5 N, 2 x 50 mL). The combined basic extracts were washed with ether (25 mL), acidified with concentrated HCl (ca. 4 mL) and extracted with ether (3 x 50 mL). The combined ether extracts were washed with water (50 mL), brine (50 65 100798 mL) and dried (MgSO 4). The solvent was removed under reduced pressure to give 2,4,5-trifluoro-3- (trifluoromethyl) benzoic acid (4.21 g, 69%) as white microscopic needles, m.p. was 87-90 ° C.

NMR (CDCl 3): 611.80 (1H, broad s, OH), 8.05 (1H, d of t, = 6 Hz, Jf = aromatic 9 Hz).

Example MM

N- (2-hydroxy-l, 1-dimethylethyl) -2,4,5-trifluoro-3- (trlfluorimetyyli) bentsamldi

A solution of 4.88 g (20.0 mmol) of 2,4,5-trifluoro-3- (trifluoromethyl) benzoic acid, 2.80 g (22.0 mmol) of oxalyl chloride and 50 ml of methylene chloride was treated with one drop DMF and stirred at room temperature for 4 hours. The solution was concentrated to a yellow oil which was dissolved in methylene chloride (20 mL) and added to a cold (ice bath) solution of 2.53 g (25 mmol) of triethylamine, 1.96 g (22 mmol) of 2-amino-2-methyl- style 1-propanol and 40 ml of methylene chloride. The mixture was allowed to slowly warm to room temperature overnight. The solution was poured into 50 mL of 1 N HCl and the organic layer was separated and washed with water. The solution was dried over magnesium sulfate and concentrated to give 5.81 g of the title compound as a yellow oil.

Example NN

2- (2,4,5-trifluoro-3- (trifluoromethyl) fenyyli1-4,4-l-methyl-2-oxazoline

A solution of 5.81 g (18.4 mmol) of N- (2-hydroxy-1,1-dimethylethyl) -2,4,5-trifluoro-3- (trifluoromethyl) benzamide in 100 ml of chloroform at 0 ° In C, was treated dropwise with 5 ml of thionyl chloride. The mixture was allowed to warm to room temperature overnight. The solution was concentrated to a yellow oil which was dissolved in 20 mL of DMF and treated with 0.8 g (21.6 mmol) of 60% sodium 6600798 umhydride. This reaction mixture was stirred at room temperature for 18 hours, then poured into 50 mL of dilute NaHCO 3. The solution was extracted with ethyl acetate, the organic phase was washed with water and dried over magnesium sulfate. Concentration in vacuo gave an orange oil which was chromatographed on silica gel eluting with 2% methanol in chloroform to give 2.62 g of a yellow oil.

Example 00 2- [2,4,5-Trifluoro-3- (trifluoromethyl) -6-methylphenyl] -4,4-dimethyl-2-oxazoline

A solution of 1.12 g (11.0 mmol) of diisopropylamine in 5 mL of THF was cooled to 0 ° C under nitrogen and treated with 4.0 mL of 2.5 M n-butyllithium. and stirred for 10 minutes. This lithium diisopropylamide solution was added dropwise to a solution of 2.36 g (8 mmol) of 2- [2,4,5-trifluoro-3- (trifluoromethyl) phenyl] -4,4-dimethyl-2-oxazoline. In 5 mL of THF at -78 ° C. The solution was stirred at -78 ° C for one hour, after which the reaction was quenched with 2.24 g (16 mmol) of methyl iodide. The mixture was allowed to slowly warm to room temperature, stirred for one hour and poured into 10 mL of 1 N HCl. This solution was extracted with ether and the extract was washed with water, dried over magnesium sulfate and concentrated to give 2.28 g of the title compound.

Example PP

3- (exo-amino) -8-azabicyclo [3.2.3] octane dihydrochloride * t

A mixture of 4.6 g (20 mmol) of 8- (phenylmethyl) -8-azabicyclo [3.2.1] octan-3-one oxime [JRBagley and TNRiley, J.Heterocyclic Chem., Lj ?, 485 ( 1982)], 0.5 g of 10% rhodium / carbon catalyst and 100 ml of acetic acid were hydrogenated until sufficient hydrogen was consumed. The reaction mixture was filtered and two equivalents of HCl were added. The solid was filtered to give 2.80 g of the title compound, m.p. was> 300 eC.

Example QQ

3- (endo-amino) -8-azabicyclo [3.2.11] octane dihydrochloride

A solution of 7.33 g (25 mmol) of 3- (endo-amino) -8- (phenylmethyl) -8-azabicyclo [3.2.1] octane dihydrochloride [P.Dostert et al., Eur.J. Med.Chem.-Chim.Ther., 19, 105 (1984)], 1.0 g of 20% palladium / carbon catalyst and 100 methanol were hydrogenated until sufficient hydrogen was consumed. The reaction mixture was filtered and the filtrate was evaporated to give 4.5 g of the title compound which was used crude.

Example 1 1-Cyclopropyl-6,8-difluoro-1,4-dihydro-5-methyl-4-oxo-7- (1-piperazinyl) -3-chlorolinecarboxylic acid

A suspension of 0.85 g (2.85 mmol) of 1-cyclopropyl-6,7,8-trifluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid, 1, 00 g (11.6 mmol) of anhydrous piperazine and 20 ml of acetonitrile were refluxed for 5 hours, followed by stirring at room temperature overnight. The precipitate was filtered, washed with water and acetonitrile and dried to give 0.91 g of the title compound, m.p. was 205-206 • C.

Example 2 '· 7- (3-Amino-1-pyrrolidinyl) -1-cyclopropyl-6,8-difluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid

A mixture of 1.00 g (3.36 mmol) of 1-cyclopropyl-6,7,8-trifluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid 0.63 g ( 3.38 mmol) of 3- (tert-butoxycarbonyl) aminopyrrolidine, 1.00 g (9.91 mmol) of tri-68 100798 ethylamine and 35 ml of acetonitrile were refluxed for 5 hours, followed by stirring at room temperature overnight. over. The precipitate was filtered and washed with acetonitrile and ether. The crude product was suspended in 20 ml of 6 M hydrochloric acid and 20 ml of glacial acetic acid and heated at 60 ° C for 2 hours. The solution was concentrated to an oil which was triturated with isopropanol. The solid was filtered and washed with ether to give 1.04 g of the title compound as the hydrochloride salt, m.p. was> 300 eC.

Example 3 1-Cyclopropyl-7- [3- (ethyl) methyl] -1-pyrrolidinyl] -6,8-difluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid

A mixture of 0.80 g (2.70 mmol) of 1-cyclopropyl-6,7,8-trifluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid, 0.41 g (3 , 20 mmol) of N-ethyl-3-pyrrolidinemethanamine, 0.82 g (8.10 mmol) of triethylamine and 25 ml of acetonitrile were refluxed for 4 hours, followed by stirring at room temperature overnight. The precipitate was filtered, washed with acetonitrile and ether and dried to give 0.90 g of the title compound, m.p. was 198-199 ° C.

Example 4 7- [3- (Aminomethyl) -3-methyl-1-pyrrolidinyl] -1-cyclopropyl-6,8-difluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid

A mixture of 0.60 g (2.02 mmol) of 1-cyclopropyl-6,7,8-trifluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid, 0.28 g (2 , 45 mmol) of 3-methyl-3-pyrrolidinemethanamine, 0.61 g (6.06 mmol) of triethylamine and 20 ml of acetonitrile were refluxed for 4 hours, followed by stirring at room temperature 69-100798 overnight. The precipitate was filtered, washed with ether and dried to give 0.61 g of the title compound, m.p. was 182-184 eC.

Example 5 1-Cyclopropyl-e, 8-difluoro-1,4-dihydro-5-methyl-7- [3-methyl-1-piperazinyl] -4-oxo-3-chloro-11-carboxylic acid

A suspension of 0.80 g (2.69 mmol) of 1-cyclopropyl-6,7,8-trifluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid, 1, 08 g (10.8 mmol) of 2-methylpiperazine and 20 ml of acetonitrile were refluxed for 3 hours, then cooled in an ice bath. The precipitate was filtered, washed with water and acetonitrile and dried to give 0.76 g of the title compound, m.p. was 187-188 BC.

Example 6 1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-7- (1-piperazinyl) -3-quinolinecarboxylic acid

A suspension of 0.70 g (2.50 mmol) of 1-cyclopropyl-6,7-difluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid, 0.86 g (10.0 mmol) of anhydrous piperazine and 20 ml of acetonitrile were refluxed for 5 hours, followed by stirring at room temperature overnight. The precipitate was filtered, washed with water and acetonitrile and dried to give 0.85 g of the title compound, m.p. was 226-228 eC.

Example 7 1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7- (3-methyl-1-piperazinyl) -4-oxo-3-quinolinecarboxylic acid

A mixture of 0.75 g (2.68 mmol) of 1-cyclopropyl-6,7-difluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid 100798 70 carboxylic acid, 1.07 g (10.4 mmol) of 2-methylpiperazine and 30 ml of acetonitrile were refluxed for 5 hours, followed by stirring at room temperature overnight. The precipitate was filtered, washed with water / ethanol and acetonitrile and dried to give 0.42 g of the title compound, m.p. was 189-192 eC.

Example 8 7- (3-Amino-1-pyrrolidinyl) -1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid

A mixture of 0.70 g (2.50 mmol) of 1-cyclopropyl-6,7-difluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid, 0.56 g (3.00 mmol) mmol) of 3- (tert-butoxycarbonyl) aminopyrrolidine, 0.76 g (7.52 mmol) of triethylamine and 25 ml of acetonitrile were refluxed for 4.5 hours, then stirred at room temperature overnight. The solids were filtered and washed with acetonitrile and ether. The crude product was dissolved in 20 ml of 6 N hydrochloric acid and 20 ml of acetic acid and stirred at room temperature for 3 hours. The solution was concentrated to an oil which was triturated with a 2: 1 mixture of ether and isopropanol. The solids were filtered and washed with ether to give 0.95 g of the title compound as the hydrochloride salt, m.p. was> 300 ° C.

Example 9 7- [3- (Aminomethyl) -3-methyl-1-pyrrolidinyl] -1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid

A mixture of 0.61 g (2.18 mmol) of 1-cyclopropyl-6,7-difluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid, 0.56 g (2.61 mmol) mmol) of 3 - [(tert-butoxycarbonyl) aminomethyl] -3-methylpyrrolidine, 0.66 g of 100798 71 (6.54 mmol) of triethylamine and 25 ml of acetonitrile were refluxed for 6 hours, followed by stirring at room temperature overnight. . The precipitate was filtered and washed with acetonitrile and ether. The crude product was suspended in 20 ml of 6 N hydrochloric acid and 20 ml of glacial acetic acid and stirred at room temperature for 3 hours. The solution was concentrated and the residue was triturated with ether. The solid was filtered and washed with ether to give 0.61 g of the title compound as the hydrochloride, m.p. was 250-252 ° C.

Example 10 8-Chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-7- (1-piperazinyl) -3-chloro-11-carboxylic acid

A suspension of 0.38 g (1.21 mmol) of 8-chloro-1-cyclopropyl-6,7-difluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid, 0.42 g (4.88 mmol) piperazine and 20 mL acetonitrile were refluxed for 4 hours, then stirred at room temperature overnight. The precipitate was filtered and washed with water and acetonitrile to give 0.32 g of the title compound, m.p. was 234-235 eC.

Example 11 7- (3-Amino-1-pyrrolidinyl) -8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-chlorolinecarboxylic acid

A mixture of 0.50 g (1.60 mmol) of 8-chloro-1-cyclopropyl-6,7-difluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid , 0.36 g (1.93 mmol) of 3- (tert-butoxycarbonyl) aminopyrrolidine, 0.48 g (4.75 mmol) of triethylamine and 20 ml of acetonitrile were refluxed under cooling for 4 hours, followed by stirring at room temperature. overnight. The solution was concentrated and the residue was triturated with a 1: 1 mixture of ether and hexane 100798 72 and filtered. The solid was washed with water and hexane. The crude product was suspended in 15 ml of dichloromethane and 1.5 ml of trifluoroacetic acid and stirred at room temperature for 4 hours. The solution was concentrated to a golden solid which was suspended in water, basified (pH 11) with 10% sodium hydroxide and filtered. The solution was then neutralized (pH 7.10) and the precipitate was filtered and washed with water to give 0.29 g of the title compound, m.p. was 124-126 ° C.

Example 12 1-Ethyl-6,8-difluoro-1,4-dihydro-5-methyl-4-oxo-7- (1-piperazinyl) -3-quinolinecarboxylic acid

A mixture of 0.45 g (1.58 mmol) of 1-ethyl-6,7,8-trifluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid, 0.54 g (6.27 mmol) of anhydrous piperazine and 20 ml of acetonitrile were refluxed for 3 hours, then cooled to room temperature. The solids were filtered and washed with water, acetonitrile and ether to give 0.48 g of the title compound, m.p. was 223-225 eC.

Example 13 7- (3-Amino-1-pyrrolidinyl) -1-ethyl-6,8-difluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid

A mixture of 0.36 g (1.25 mmol) of 1-ethyl-6,7,8-trifluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid, 0.26 g (1.39 mmol) of 3- (tert-butoxycarbonyl) aminopyrrolidine, 0.38 g (3.76 mmol) of triethylamine and 20 ml of acetonitrile were refluxed for 5 hours, then stirred at room temperature overnight. The solids were filtered and washed with acetonitrile and ether. The crude product was dissolved in 5 ml of 6 N hydrochloric acid and 5 ml of glacial acetic acid and stirred for 5 hours at room temperature. The solution was concentrated to a solid which was suspended in water, basified (pH 12), filtered through a pad of glass fiber and neutralized (pH 6.8). The solids were filtered and washed with water to give 0.32 g of a white solid, m.p. was 218-220 eC.

Example 14 6,8-Difluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-11-4-oxo-7- (1-piperazinyl) -3-quinolinecarboxylic acid

A solution of 0.43 g (1.08 mmol) of ethyl 6,7,8-trifluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-4-oxo- 3-Quinolinecarboxylic acid, 0.37 g (4.30 mmol) of anhydrous piperazine and 20 mL of acetonitrile were refluxed overnight, cooled to room temperature and concentrated. The residue was taken up in 10 ml of 6 N hydrochloric acid and refluxed for 2 hours. The mixture was cooled and the solids were filtered. The crude product was suspended in water, basified (pH 12), filtered through a pad of glass fiber and neutralized (pH 6.5). The solids were filtered and washed with water and ether to give 0.37 g of the title compound, m.p. was 283-284 ° C.

The following compound was prepared by the same method: a) 6,8-difluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-7- (3,5-dimethyl-1-piperazinyl) -4- oxo-3-quinolinecarboxylic acid, m.p. 240-242 eC.

: Example 15 7- (3-Amino-1-pyrrolidinyl) -6,8-difluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxyl -syylihappo

A solution of 0.40 g (1.00 mmol) of ethyl 6,7,8-trifluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-4- 74 100798 oxo-3-quinolinecarboxylic acid, 0.22 g (1.18 mmol) of 3- (tert-butoxycarbonyl) aminopyrrolidine, 0.30 g (3.00 mmol) of triethylamine and 15 ml of acetonitrile were refluxed for 18 hours. The mixture was cooled and concentrated. The residue was dissolved in 10 ml of 6 N hydrochloric acid, refluxed for 3 hours and cooled to room temperature. The solids were filtered, washed with water and ether and suspended in water. The suspension was basified (pH 12) and filtered through a pad of glass fiber and the filtrate was neutralized to pH 6.7. The solids were filtered and washed with water and ether to give 0.38 g of the title compound, m.p. was 230-232 eC.

Example 16 6,8-Difluoro-1,4-dihydro-5-methyl-4-oxo-7- (1-piperazinyl) -1-vinyl-3-quinolinecarboxylic acid

A solution of 0.69 g (1.80 mmol) of ethyl 6,7,8-trifluoro-1,4-dihydro-5-methyl-4-oxo-1-vinyl-3-quinolinecarboxylate, 0.62 g (7.2 mmol) of anhydrous piperazine and 20 ml of acetonitrile were refluxed for 18 hours, cooled and concentrated. The residue was suspended in 25 ml of 1 N sodium hydroxide and heated at 80 ° C for 90 minutes. The clear, yellow solution was cooled to room temperature, filtered and neutralized (pH 6.8) with 6 N hydrochloric acid. The solids were filtered, washed with water and ether and dried to give 0.32 g of the title compound, m.p. was 222-225 ° C.

The following compound was prepared in a similar manner: a) 6,8-Difluoro-1,4-dihydro-5-methyl-7- (3-methyl-1-piperazinyl) -1-vinyl-3-quinolinecarboxylic acid, m.p. 232-235 eC.

75 100798

Example 17 6-Fluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-4-oxo-7- (1-piperazinyl) -3-quinolinecarboxylic acid

A solution of 0.76 g (2.00 mmol) of ethyl 6,7-difluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-4-oxo-3- quinolinecarboxylate, 0.69 g (8.00 mmol) of anhydrous piperazine and 30 mL of acetonitrile were refluxed for 18 hours, cooled and concentrated. The residue was dissolved in 20 ml of 6 N hydrochloric acid and refluxed for 3 hours. The suspension was cooled, concentrated to half volume and filtered and the solids were washed with water. The crude product was suspended in water, basified (pH 12), filtered and neutralized to pH 6.8. The precipitate was filtered, washed with water and dried to give 0.58 g of the title compound, m.p. was 198-200 BC.

The following compounds were prepared using essentially the same procedure: a) 6-Fluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-7- (3-methyl-1-piperazinyl) -4-oxo- 3-quinolinecarboxylic acid, m.p. 188-191 ° C; b) 6-fluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-7- (3,5-dimethyl-1-piperazinyl) -4-oxo-3-quinolinecarboxylic acid, mp 213-215 ° C; c) 7- (3-amino-1-pyrrolidinyl) -6-fluoro-1- (2,4-difluoro-phenyl) -1,4-dihydro-5-methyl-4-oxo-3-quinolinylcarboxylic acid, mp 232-234 ° C; d) 7- [3- (ethylamino) methyl-1-pyrrolidinyl] -6-fluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid, m.p. p. 196-198 ° C and e) 7- [3- (aminomethyl) -3-methyl-1-pyrrolidinyl] -6-fluoro-1- (2,4-difluorophenyl) -1,4-dihydro-5-methyl-4- oxo-3-chlorolinylcarboxylic acid, m.p. 181-184 eC.

76 100798

Example 18 7- (3-Amino-1-pyrrolidinyl) -1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid

Triethylamine (0.17 mL, 1.2 mmol), 3- (1,1-dimethylethoxycarbonylamino) pyrrolidine (0.22 g, 2.1 mmol) and 0.39 g (1.2 mmol) of 7- Chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-1,1-naphthyridine-5-carboxylic acid ethyl ester was dissolved in acetonitrile (10 ml) and the mixture was heated under reflux for 4 hours, then cooled. and diluted with ether (50 mL). This solution was washed with saturated KHCO 3 and NaCl solutions and dried over Na 2 SO 4. The addition of O 2 Cl 2 was necessary to maintain the homogeneity of the solution. It was filtered and evaporated, after which the product obtained was dissolved in ether and allowed to stand. The formed crystals were collected, yielding 0.56 g of intermediate ester. The intermediate ester was dissolved in acetic acid (15 mL) and 6 N HCl (1 mL) was added and the mixture was heated to reflux for 2 hours, after which it was evaporated to a gum. This gum was dissolved in ethanol (10 mL) and 5 N NaOH (2 mL) was added and the mixture was stirred for 2 hours. The reaction mixture was evaporated to a gum and dissolved in water (60 ml) to give a solution having a pH of 12. The pH was adjusted to 6.5 and the resulting solid was collected and washed with water and dried to give the title compound (0.38 g).

Example 19 1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-7- (1-piperazinyl) -1,8-naphthyridine-3-carboxylic acid The procedure described in Example 18 was used to prepare the title compound. compound in 58% yield.

77 100798

Example 20 1-Ethyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo- (1-piperazinyl) -3-chlorocarbonyl acid

A suspension of 0.67 g (2.50 mmol) of 1-ethyl-6,7-difluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid, 0.86 g (10 .0 mmol) of anhydrous piperazine and 25 ml of acetonitrile were refluxed for 6 hours, then cooled to room temperature. The solids were filtered, washed with water and ether and dried to give 0.58 g of the title compound, m.p. was 225-227 ° C.

The following compounds were prepared using essentially the same procedure: a) 1-ethyl-7- [3- (ethylamino) methyl] -1-pyrrolidinyl] -6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylate -acylic acid, m.p. 180-182 ° C; b) 7- (3-amino-1-pyrrolidinyl) -1-ethyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid, m.p. 210-213 #C; c) 1-Ethyl-6-fluoro-1,4-dihydro-5-methyl-7- (3-methyl-1-piperazinyl) -4-oxo-3-quinolinecarboxylic acid, m.p. 228-231 ° C; d) 1-ethyl-6-fluoro-1,4-dihydro-5-methyl-7- (3,5-dimethyl-1-piperazinyl) -4-oxo-3-quinolinecarboxylic acid, m.p. 219-221 ° C; e) 7- (3- (aminomethyl) -3-methyl-1-pyrrolidinyl] -1-ethyl-6-fluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid, m.p. 223-225 eC.

«78 100798

Example 21 7- [3- (Endo-amino) -8-azabicycloro 3 ♦ 2-oct-8-yl] -8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl- 4-oxo-3-quinolinecarboxylic acid

A mixture of 0.50 g (1.6 mmol) of 8-chloro-1-cyclopropyl-6,7-difluoro-1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid, 0.36 g (1.8 mmol) of 3- (endo-amino) -8-azabicyclo [3.2.1] octane dihydrochloride, 0.72 ml (4.8 mmol) of 1,8-diazabicyclo [5.4.0] undec-7-ene and 15 ml of acetonitrile, was refluxed for 18 hours. The suspension was cooled to room temperature, diluted with ether and cooled. The resulting solid was filtered, washed with ethanol and ether and dried to give the title compound.

The following compounds were prepared in a similar manner: Example a: 7- [3- (endo-amino) -8-azabicyclo [3.2.1] oct-8-yl] -6,8-difluoro-1- (2,4-difluorophenyl) -l, 4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acid.

Example b: 7- [3- (endo-amino) -8-azabicyclo [3.2.1] oct-8-yl] -1-cyclopropyl-6,8-difluoro-1,4-dihydro-5-methyl-4 - oxo-3-quinolinecarboxylic acid.

Claims (1)

100798 Patent Method for preparing a compound of formula R fJvC00H, V. F wherein R is alkyl, characterized in that 2-pentafluorophenyl-4,4-dimethyl-2-oxazoline is reacted with an alkyllithium corresponding to the group R to give a compound of formula, followed by acid hydrolysis. 100798 For the preparation of a formulation with the formula RF ^ L / COOH F color R is en alkyl, the same is used to give 2-pentafluoro-phenyl-4,4-dimethyl-2-oxazoline in the form of alkyllithium, in which the group R, for the purposes of the formulation, f '^ V ^' f F varefter man utför syrahydrolys.